WEBVTT

00:00:00.000 --> 00:00:02.299
Imagine this scenario for a moment. You are standing

00:00:02.299 --> 00:00:06.339
at the pharmacy counter. Right. And you are holding

00:00:06.339 --> 00:00:07.839
your breath. Your heart is pounding a little

00:00:07.839 --> 00:00:09.800
bit in your chest. Because you are terrified

00:00:09.800 --> 00:00:12.099
of what the pharmacist is about to say. Exactly.

00:00:12.179 --> 00:00:14.359
You just got a prescription for a life saving

00:00:14.359 --> 00:00:18.239
medication. Something you, or maybe a loved one,

00:00:18.559 --> 00:00:21.539
absolutely needs to survive. The pharmacist taps

00:00:21.539 --> 00:00:24.879
a few keys. They look at the screen. And then

00:00:24.879 --> 00:00:28.839
they look up at you with this sympathetic wince.

00:00:29.070 --> 00:00:32.289
Oh, that is the worst feeling. It is. And they

00:00:32.289 --> 00:00:36.590
tell you your total is $800. Wow. For a one -month

00:00:36.590 --> 00:00:39.590
supply. You feel that sinking sensation in your

00:00:39.590 --> 00:00:41.649
chest. You know, that sudden panic of wondering

00:00:41.649 --> 00:00:43.990
how on earth you're going to pay the rent, buy

00:00:43.990 --> 00:00:46.109
groceries, and afford to stay alive all at the

00:00:46.109 --> 00:00:48.929
exact same time. It is a terrifying reality for

00:00:48.929 --> 00:00:51.170
so many people. Welcome to the Deep Dive. We

00:00:51.170 --> 00:00:53.229
are so glad you are joining us today because

00:00:53.229 --> 00:00:55.869
that terrifying scenario at the pharmacy counter

00:00:55.869 --> 00:00:58.789
is not just some hypothetical fear. Not at all.

00:00:58.840 --> 00:01:01.740
It is the lived reality for millions of Americans

00:01:01.740 --> 00:01:04.299
navigating a system that often feels like it

00:01:04.299 --> 00:01:07.120
was designed to confuse and just completely bankrupt

00:01:07.120 --> 00:01:09.640
them. Yeah, it really does feel intentional sometimes.

00:01:10.159 --> 00:01:12.079
Today, we are looking at the radical ongoing

00:01:12.079 --> 00:01:14.840
transformation of the United States pharmaceutical

00:01:14.840 --> 00:01:18.620
supply chain, specifically looking at 2025 and

00:01:18.620 --> 00:01:22.079
2026. It is a massive shift. It is. And we have

00:01:22.079 --> 00:01:24.000
a huge stack of sources to get through to make

00:01:24.000 --> 00:01:26.840
sense of all this. We are pulling from deep industry

00:01:26.840 --> 00:01:29.459
analyses from publications like Drug Channels

00:01:29.459 --> 00:01:31.719
and Pharmaceutical Commerce. We also have some

00:01:31.719 --> 00:01:34.379
incredible peer -reviewed academic studies to

00:01:34.379 --> 00:01:36.799
look at today. Right. From JMA Network Open.

00:01:37.140 --> 00:01:39.260
Plus, we've got government policy updates and

00:01:39.260 --> 00:01:41.480
direct unfiltered insights from the Mark Cuban

00:01:41.480 --> 00:01:43.840
Cost Plus Drug Company. A lot of ground to cover.

00:01:44.000 --> 00:01:46.280
So our mission for this deep dive is to decode

00:01:46.280 --> 00:01:49.000
exactly why prescription drugs cost so much in

00:01:49.000 --> 00:01:51.359
the U .S. I mean, prices here are historically

00:01:51.359 --> 00:01:54.280
two and a half times higher than in 32 other

00:01:54.379 --> 00:01:56.599
purple countries. Which is just staggering when

00:01:56.599 --> 00:01:58.920
you really think about it. It is. We are going

00:01:58.920 --> 00:02:01.840
to examine the opaque mechanics of how middlemen

00:02:01.840 --> 00:02:04.700
manipulate the system and most importantly we

00:02:04.700 --> 00:02:07.560
want to see what new transparent business models

00:02:07.560 --> 00:02:10.719
and this massive shift to domestic manufacturing

00:02:10.719 --> 00:02:13.340
actually mean for you. Right for your wallet

00:02:13.340 --> 00:02:15.180
and your health care. And the broader economy.

00:02:15.560 --> 00:02:18.919
Okay let's unpack this. We have an ecosystem

00:02:18.919 --> 00:02:21.840
that feels fundamentally broken to the person

00:02:21.840 --> 00:02:23.759
standing at the register. Absolutely broken.

00:02:23.919 --> 00:02:26.560
But it is clearly functioning exactly as intended

00:02:26.560 --> 00:02:29.879
for a select few behind the scenes. We are essentially

00:02:29.879 --> 00:02:33.400
looking at a war between an entrenched shadowy

00:02:33.400 --> 00:02:36.219
status quo and a transparent physical rebellion.

00:02:36.319 --> 00:02:38.280
That is a great way to put it. But to understand

00:02:38.280 --> 00:02:40.180
the rebellion, we really have to diagnose the

00:02:40.180 --> 00:02:42.099
underlying disease of the current system first.

00:02:42.199 --> 00:02:44.840
Well, the underlying disease is entirely rooted

00:02:44.840 --> 00:02:47.750
in information asymmetry. and really just the

00:02:47.750 --> 00:02:50.509
sheer dominance of intermediaries. OK, break

00:02:50.509 --> 00:02:52.449
that down for us. Sure. So if you look at the

00:02:52.449 --> 00:02:55.030
traditional drug supply chain on a whiteboard,

00:02:55.189 --> 00:02:57.889
it sounds relatively straightforward. Manufacturer

00:02:57.889 --> 00:03:00.710
makes a drug. Right. A pharmaceutical manufacturer

00:03:00.710 --> 00:03:03.909
makes a drug and sets a list price. Then a wholesaler

00:03:03.909 --> 00:03:07.219
buys it. moves it across the country, and distributes

00:03:07.219 --> 00:03:09.159
it. And finally, a pharmacy soars it on a shelf

00:03:09.159 --> 00:03:11.300
and dispenses it to you. Exactly, it sounds simple.

00:03:11.699 --> 00:03:13.539
But sitting right in the middle of that flow,

00:03:13.879 --> 00:03:16.080
extracting immense value without ever actually

00:03:16.080 --> 00:03:18.639
touching a single pill, is the pharmacy benefit

00:03:18.639 --> 00:03:22.840
manager. The PBM. The PBM. And right now, three

00:03:22.840 --> 00:03:26.240
major PBMs completely dominate the market. You

00:03:26.240 --> 00:03:29.159
have CVS, Caremark, OptiMark, and Express Scripts.

00:03:29.259 --> 00:03:31.500
They control the vast majority of the volume.

00:03:31.580 --> 00:03:34.080
They do. And they operate using pricing metrics

00:03:34.080 --> 00:03:36.520
that sound incredibly official, but are highly

00:03:36.520 --> 00:03:38.520
malleable. Specifically, they use the average

00:03:38.520 --> 00:03:41.240
wholesale price, or AWP. And the wholesale acquisition

00:03:41.240 --> 00:03:44.199
cost rate. Right. The WAC. Exactly. But how do

00:03:44.199 --> 00:03:46.360
those metrics actually function in the real world?

00:03:46.599 --> 00:03:49.430
Because to the average person, Average wholesale

00:03:49.430 --> 00:03:51.530
price sounds like a very fixed objective number.

00:03:51.689 --> 00:03:53.469
Right, sounds official. It sounds like the price

00:03:53.469 --> 00:03:55.330
you would pay if you walked into a giant warehouse

00:03:55.330 --> 00:03:58.169
club to buy bulk paper towels. How are these

00:03:58.169 --> 00:04:00.590
entities manipulating something that sounds so

00:04:00.590 --> 00:04:03.229
standard? Think of the average wholesale price.

00:04:03.500 --> 00:04:06.400
Less like an objective cost and more like the

00:04:06.400 --> 00:04:09.479
sticker price on a new car at a dealership. OK,

00:04:09.699 --> 00:04:11.780
nobody actually pays the sticker price. Right.

00:04:11.939 --> 00:04:14.780
Nobody pays it. But the entire industry uses

00:04:14.780 --> 00:04:17.879
it as a baseline to calculate artificial discounts.

00:04:18.600 --> 00:04:20.959
What's fascinating here is how that baseline

00:04:20.959 --> 00:04:23.879
enables what economists call the rebate distortion.

00:04:24.060 --> 00:04:26.879
The rebate distortion. OK, explain that. So PBMs

00:04:26.879 --> 00:04:30.120
negotiate massive rebates from drug manufacturers.

00:04:30.699 --> 00:04:34.120
We are talking generally between between 85 to

00:04:34.120 --> 00:04:37.240
88 % off that inflated average wholesale price.

00:04:37.360 --> 00:04:41.000
88 % off? Yes. The PBM goes to the drug maker

00:04:41.000 --> 00:04:43.379
and essentially says, hey, if you want your drug

00:04:43.379 --> 00:04:45.480
on our approved list so that millions of insured

00:04:45.480 --> 00:04:47.459
patients can actually get it, you need to give

00:04:47.459 --> 00:04:49.819
us a massive rebate off your list price. And

00:04:49.819 --> 00:04:52.079
the manufacturer just says yes. They have to

00:04:52.079 --> 00:04:54.920
comply if they want volume. But to protect their

00:04:54.920 --> 00:04:57.300
own profit margins, they artificially inflate

00:04:57.300 --> 00:04:59.120
the list price of the drug in the first place.

00:04:59.220 --> 00:05:01.220
Just to create room for the massive rebate. Exactly.

00:05:02.060 --> 00:05:04.160
The manufacturer raises the price from, say,

00:05:04.360 --> 00:05:08.300
$10 to $100, just so the PBM can demand an $85

00:05:08.300 --> 00:05:10.939
discount and run around claiming they saved the

00:05:10.939 --> 00:05:13.079
system money. That is exactly how it works. That

00:05:13.079 --> 00:05:16.379
is absurd. But where does that $85 actually go?

00:05:16.779 --> 00:05:18.639
Does it go back to the patient at the pharmacy

00:05:18.639 --> 00:05:22.420
counter? Rarely. Conventionally, the PBM keeps

00:05:22.420 --> 00:05:24.939
a percentage of the rebate they negotiated before

00:05:24.939 --> 00:05:27.180
passing the rest on to the employer or the health

00:05:27.180 --> 00:05:29.800
plan sponsor. Let's look at the math provided

00:05:29.800 --> 00:05:32.240
in these industry analyses to really nail this

00:05:32.240 --> 00:05:34.639
down. Sure. Let's assume a hypothetical generic

00:05:34.639 --> 00:05:39.779
drug has an AWP of $100. $500 on paper. The PBM

00:05:39.779 --> 00:05:42.600
negotiates that massive discount, bringing the

00:05:42.600 --> 00:05:45.540
actual acquisition cost of the drug down to $15.

00:05:45.980 --> 00:05:49.639
So they knock $85 off. Right. But the PBM decides

00:05:49.639 --> 00:05:52.720
to keep a percentage of that original AWP rebate

00:05:52.720 --> 00:05:54.750
for themselves. Just for doing the negotiations.

00:05:55.069 --> 00:05:57.490
Yes. So suddenly the price of the drug bill to

00:05:57.490 --> 00:06:00.350
the payer is twenty three dollars and fifty cents.

00:06:00.750 --> 00:06:03.689
The PPM just pocketed eight dollars and fifty

00:06:03.689 --> 00:06:06.329
cents on a drug that only cost fifteen dollars

00:06:06.329 --> 00:06:09.329
to acquire. They extracted more than 50 percent

00:06:09.329 --> 00:06:12.810
of the drugs value just for processing a transaction.

00:06:13.170 --> 00:06:15.610
Precisely. That seems like an unsustainable grift

00:06:15.610 --> 00:06:18.350
to me. If employers and health plan sponsors

00:06:18.350 --> 00:06:20.490
are the ones actually footing the bill for this.

00:06:20.839 --> 00:06:22.819
Why wouldn't they just look at the contract,

00:06:23.180 --> 00:06:26.459
see the $8 .50 being skimmed, and demand a better

00:06:26.459 --> 00:06:28.459
deal? Because they can't see it. They can't see

00:06:28.459 --> 00:06:31.019
their own contracts. The contracts are notoriously

00:06:31.019 --> 00:06:34.860
opaque. Large PBMs have created entirely new

00:06:34.860 --> 00:06:38.079
layers of subsidiary entities specifically to

00:06:38.079 --> 00:06:40.060
off the skate the money trail. What kind of entities?

00:06:40.579 --> 00:06:43.259
They set up organizations called rebate aggregators

00:06:43.259 --> 00:06:46.379
or group purchasing organizations. And many of

00:06:46.379 --> 00:06:49.480
these entities are purposefully domiciled internationally.

00:06:49.620 --> 00:06:52.220
Like overseas? Yes, in places like Switzerland

00:06:52.220 --> 00:06:55.160
or Ireland. And they do this specifically to

00:06:55.160 --> 00:06:57.699
prevent domestic audits and avoid transparency

00:06:57.699 --> 00:07:00.079
requirements. That is unbelievable. Estimates

00:07:00.079 --> 00:07:02.800
suggest another 8 % of rebates might be captured

00:07:02.800 --> 00:07:05.040
right at this international subsidiary level.

00:07:05.300 --> 00:07:08.000
So that hypothetical $15 drug is now costing

00:07:08.000 --> 00:07:11.279
the system over $30. Easily. The list prices

00:07:11.279 --> 00:07:13.600
are artificially inflated, the rebates are squeezed

00:07:13.600 --> 00:07:16.319
out, and the money just vanishes into offshore

00:07:16.319 --> 00:07:18.959
entities before the employer ever sees the final

00:07:18.959 --> 00:07:22.509
accounting. It's a black box. It is. And on top

00:07:22.509 --> 00:07:25.129
of that, PBMs charge a litany of fees to the

00:07:25.129 --> 00:07:27.389
pharmaceutical companies. Or fees. Oh, yeah.

00:07:27.829 --> 00:07:32.089
As of 2021, 29 % of PBM revenue was estimated

00:07:32.089 --> 00:07:35.189
to come strictly from administrative fees. 29%.

00:07:35.189 --> 00:07:38.959
Yes. That is a massive jump from 15 % back in

00:07:38.959 --> 00:07:41.360
2015. What are they charging for? Promotional

00:07:41.360 --> 00:07:45.220
allowances, implementation allowances, formulary

00:07:45.220 --> 00:07:48.860
placement fees, data fees. It is literally a

00:07:48.860 --> 00:07:51.639
toll booth on every single inch of the supply

00:07:51.639 --> 00:07:54.040
chain. Mark Cuban recently wrote a guest post

00:07:54.040 --> 00:07:56.319
on the Drug Channel's blog outlining this exact

00:07:56.319 --> 00:07:58.860
dysfunction. It was a very pointed post. He laid

00:07:58.860 --> 00:08:01.379
out a framework of major criticisms against how

00:08:01.379 --> 00:08:04.000
these big PBMs operate. And you just hit on the

00:08:04.000 --> 00:08:06.819
first one perfectly. absolute zero transparency.

00:08:07.120 --> 00:08:09.779
Right. You can't see the math. He noted that

00:08:09.779 --> 00:08:12.579
the primary rule of contracting with a PBM is

00:08:12.579 --> 00:08:15.279
that you are legally barred from talking about

00:08:15.279 --> 00:08:17.420
the PBM or the specifics of their contracts.

00:08:17.540 --> 00:08:20.699
It's like Fight Club rules. Exactly. Yeah. Providers,

00:08:20.959 --> 00:08:23.019
manufacturers, employers and non -affiliated

00:08:23.019 --> 00:08:25.259
pharmacies are all legally gagged. It protects

00:08:25.259 --> 00:08:27.660
the margin. But he also talked about how this

00:08:27.660 --> 00:08:29.939
impacts the physical categorization of the drugs

00:08:29.939 --> 00:08:33.169
themselves. He used the term magic names. Magic

00:08:33.169 --> 00:08:36.649
names, yes. How does a PBM magically rename a

00:08:36.649 --> 00:08:39.669
drug to extract more money? They utilize their

00:08:39.669 --> 00:08:42.210
absolute control over the formulary, the master

00:08:42.210 --> 00:08:44.990
list of covered drugs. Right. A PBM can take

00:08:44.990 --> 00:08:47.909
a standard small molecule generic drug that has

00:08:47.909 --> 00:08:50.590
been on the market for years, and they just arbitrarily

00:08:50.590 --> 00:08:53.330
reclassify it as a specialty drug. Is there a

00:08:53.330 --> 00:08:56.120
medical reason for that? Often, there is absolutely

00:08:56.120 --> 00:08:58.980
no clinical justification for it. The drug doesn't

00:08:58.980 --> 00:09:01.100
suddenly require a compliance refrigeration or

00:09:01.100 --> 00:09:03.100
special handling. It's the same exact pill. Same

00:09:03.100 --> 00:09:05.980
pill. But by slapping the specialty label on

00:09:05.980 --> 00:09:09.519
it, the PBM can force the patient to bypass their

00:09:09.519 --> 00:09:12.080
local community pharmacy. And mandate that they

00:09:12.080 --> 00:09:14.500
use a mail order specialty pharmacy. Exactly.

00:09:14.700 --> 00:09:17.000
A specialty pharmacy that is wholly owned by

00:09:17.000 --> 00:09:20.100
the PBM itself. Ah, so they force the volume

00:09:20.100 --> 00:09:22.480
to their own subsidiary. Yes. And once the drug

00:09:22.480 --> 00:09:24.559
is channeled through their captive, wholly -owned

00:09:24.559 --> 00:09:28.039
firmacy, they can charge the health plan exponentially

00:09:28.039 --> 00:09:30.399
more than the drug is actually worth on the open

00:09:30.399 --> 00:09:32.419
market. Because there's no competition. None.

00:09:32.679 --> 00:09:34.740
They dictate the rules of the game, and they

00:09:34.740 --> 00:09:37.419
own the board the game is played on. Let's ground

00:09:37.419 --> 00:09:39.639
this in a real -world example so you listening

00:09:39.639 --> 00:09:42.299
can truly grasp the scale of the financial pain

00:09:42.299 --> 00:09:45.470
this causes. Let's look at the chemotherapy drug

00:09:45.470 --> 00:09:48.429
Imatinib. The generic version of Gleevec. Right.

00:09:48.610 --> 00:09:50.870
It's a leukemia treatment. It has been around

00:09:50.870 --> 00:09:54.190
for a very long time. It is a standard generic

00:09:54.190 --> 00:09:56.950
small molecule pill. Nothing fancy about the

00:09:56.950 --> 00:09:59.649
physical pill itself. If a patient gets diagnosed

00:09:59.649 --> 00:10:01.750
with leukemia and they happen to be on a high

00:10:01.750 --> 00:10:05.470
deductible health plan, what does this PBM pricing

00:10:05.470 --> 00:10:07.129
maze look like for them when they try to get

00:10:07.129 --> 00:10:10.049
this life -saving generic? Under the traditional

00:10:10.049 --> 00:10:12.929
convoluted PBM system, the adjudicated price

00:10:12.929 --> 00:10:16.049
can be staggering. The adjudicated price, meaning

00:10:16.049 --> 00:10:19.389
the final price negotiated by the PBM that the

00:10:19.389 --> 00:10:21.590
patient is responsible for before they hit their

00:10:21.590 --> 00:10:23.870
deductible. Correct. A patient might be asked

00:10:23.870 --> 00:10:28.169
to pay anywhere from $2 ,000 to $3 ,200 for a

00:10:28.169 --> 00:10:30.889
single one -month supply of generic imatinib.

00:10:30.990 --> 00:10:34.929
Over $3 ,000. For a generic, yes, that is thousands

00:10:34.929 --> 00:10:37.399
of dollars out of pocket. The system requires

00:10:37.399 --> 00:10:39.940
the patient to absorb the inflated list price

00:10:39.940 --> 00:10:42.539
until their massive deductible is fully met.

00:10:43.059 --> 00:10:45.200
And this brings up a massive point of friction.

00:10:45.879 --> 00:10:49.179
If an employer signs a contract with a PBM, they

00:10:49.179 --> 00:10:51.240
might think they're getting a great deal because

00:10:51.240 --> 00:10:54.799
the PBM promises them a large rebate check at

00:10:54.799 --> 00:10:57.019
the end of the year. They love that rebate check.

00:10:57.120 --> 00:10:59.980
Right. And the employer uses that check to lower

00:10:59.980 --> 00:11:02.000
the overall health care premiums for the entire

00:11:02.000 --> 00:11:04.299
company. Yeah. But who is actually funding that

00:11:04.299 --> 00:11:06.970
rebate check? It isn't the drug manufacturer

00:11:06.970 --> 00:11:09.090
just freely handing out cash from their vault.

00:11:09.450 --> 00:11:11.690
Not at all. And if we connect this to the bigger

00:11:11.690 --> 00:11:14.549
picture, the reality of corporate health care

00:11:14.549 --> 00:11:17.289
financing is deeply troubling. How so? Those

00:11:17.289 --> 00:11:20.110
rebates are largely paid for by the sickest and

00:11:20.110 --> 00:11:22.750
oldest employees within a given company. Explain

00:11:22.750 --> 00:11:24.649
the mechanics of that. Because the list prices

00:11:24.649 --> 00:11:27.789
are kept artificially high to fund the rebate

00:11:27.789 --> 00:11:30.009
structure employees with chronic conditions,

00:11:30.610 --> 00:11:32.789
they hit their high deductibles very quickly.

00:11:33.019 --> 00:11:36.379
Like the leukemia patient needing Imatinib? Exactly.

00:11:36.700 --> 00:11:39.840
Or someone managing diabetes or rheumatoid arthritis.

00:11:40.240 --> 00:11:42.659
They are paying those inflated thousands of dollars

00:11:42.659 --> 00:11:45.320
prices out of pocket. Using their own after -tax

00:11:45.320 --> 00:11:48.379
income? Yes. The PBM aggregates that overpayment,

00:11:48.399 --> 00:11:50.799
takes its cut, and hands the remainder back to

00:11:50.799 --> 00:11:52.580
the employer. And what does the employer do with

00:11:52.580 --> 00:11:56.059
it? The employer then applies that money to lower

00:11:56.059 --> 00:11:58.919
the monthly premium for the 25 -year -old employee

00:11:58.919 --> 00:12:01.889
who never goes to the doctor. Wow. So essentially,

00:12:02.129 --> 00:12:03.990
healthcare within the modern corporate structure

00:12:03.990 --> 00:12:07.129
functions as a regressive tax. A massively regressive

00:12:07.129 --> 00:12:10.629
tax. The sick employees are actively and disproportionately

00:12:10.629 --> 00:12:12.830
subsidizing the healthcare costs of the healthy

00:12:12.830 --> 00:12:16.070
employees. While the PBM skims a massive, multi

00:12:16.070 --> 00:12:19.070
-billion dollar margin off the top just for facilitating

00:12:19.070 --> 00:12:21.389
the transfer. It is incredibly efficient for

00:12:21.389 --> 00:12:24.309
the PBM, but devastating for the patients. When

00:12:24.309 --> 00:12:27.730
you map out the mechanics like that, it is genuinely

00:12:27.730 --> 00:12:30.940
enraging. The sickest people at the absolute

00:12:30.940 --> 00:12:33.659
most vulnerable moments of their lives are being

00:12:33.659 --> 00:12:36.519
used as a funding mechanism for corporate premium

00:12:36.519 --> 00:12:39.919
reductions and offshore middleman profits. It

00:12:39.919 --> 00:12:41.980
is hard to justify when you see the math bear

00:12:41.980 --> 00:12:44.620
like that. Cuban also pointed out how this system

00:12:44.620 --> 00:12:47.620
financially abuses independent community pharmacies.

00:12:47.840 --> 00:12:50.440
The mom and pop shops. Right. They are subjected

00:12:50.440 --> 00:12:53.559
to aggressive audit tactics and forced to accept

00:12:53.559 --> 00:12:55.940
reimbursement rates that are often lower than

00:12:55.940 --> 00:12:57.799
the cost they paid to acquire the drug in the

00:12:57.799 --> 00:13:00.240
first place. They're forced to take a loss just

00:13:00.240 --> 00:13:02.740
to serve their patients. But diagnosing the disease

00:13:02.740 --> 00:13:05.139
is only the first step. The market is finally

00:13:05.139 --> 00:13:07.799
responding. We're seeing real pushback. A massive

00:13:07.799 --> 00:13:10.039
structural pushback against this opaqueness.

00:13:10.399 --> 00:13:12.820
Let's look at the emergence of the un -PBM model,

00:13:13.379 --> 00:13:16.159
specifically the Mark Cuban Cost Plus drug company.

00:13:16.539 --> 00:13:19.559
MCC PDC. They are trying to build an entirely

00:13:19.559 --> 00:13:22.240
parallel supply chain. How is their corporate

00:13:22.240 --> 00:13:24.580
structure fundamentally different from the incumbents

00:13:24.580 --> 00:13:27.299
we just talked about? Well, MCC PDC was founded

00:13:27.299 --> 00:13:31.019
in 2022 by Dr. Alexander Oshmanski and Mark Cuban,

00:13:31.059 --> 00:13:34.220
and it operates as a public benefit corporation

00:13:34.220 --> 00:13:38.019
or PBC. A public benefit corporation. Why does

00:13:38.019 --> 00:13:41.179
that specific legal designation matter so much?

00:13:41.399 --> 00:13:44.019
Because that legal designation is the foundation

00:13:44.019 --> 00:13:47.080
of everything they do. A traditional C corporation,

00:13:47.220 --> 00:13:50.860
like a major PBM, has a fiduciary duty solely

00:13:50.860 --> 00:13:53.600
to maximize shareholder value. Meaning they have

00:13:53.600 --> 00:13:55.860
to make as much money as legally possible. Right.

00:13:56.159 --> 00:13:59.100
If a traditional PPM can legally extract an extra

00:13:59.100 --> 00:14:01.600
billion dollars by hiding fees in an offshore

00:14:01.600 --> 00:14:04.399
aggregator, they are essentially obligated to

00:14:04.399 --> 00:14:07.200
do so for their shareholders. But a public benefit

00:14:07.200 --> 00:14:09.480
corporation is different. Radically different.

00:14:09.659 --> 00:14:11.820
The legal charter mandates that their social

00:14:11.820 --> 00:14:14.639
mission must be prioritized alongside and sometimes

00:14:14.639 --> 00:14:17.480
even above pure financial performance. And their

00:14:17.480 --> 00:14:19.840
social mission here is improving public health

00:14:19.840 --> 00:14:22.620
through transparent, affordable medicine. Exactly.

00:14:22.820 --> 00:14:25.279
So they have fundamentally rejected the rebate

00:14:25.279 --> 00:14:27.580
-centric model. They don't negotiate rebates.

00:14:27.820 --> 00:14:29.840
They don't have offshore aggregators. They just

00:14:29.840 --> 00:14:31.899
built a vertically integrated direct -to -consumer

00:14:31.899 --> 00:14:34.940
supply chain. Using a strict cost -plus economic

00:14:34.940 --> 00:14:38.629
model. The formula for this cost plus model is

00:14:38.629 --> 00:14:41.190
almost jarringly simple when you compare it to

00:14:41.190 --> 00:14:44.029
the convoluted average wholesale price and wholesale

00:14:44.029 --> 00:14:46.149
acquisition cost metrics we just discussed. It

00:14:46.149 --> 00:14:48.409
takes 10 seconds to explain. It is literally

00:14:48.409 --> 00:14:50.970
just the actual acquisition cost of the drug,

00:14:51.429 --> 00:14:53.490
what they paid the manufacturer to make it or

00:14:53.490 --> 00:14:57.159
buy it, plus a fixed 15 % markup. to fund their

00:14:57.159 --> 00:15:01.000
operations. Plus a flat $5 pharmacy labor fee.

00:15:01.039 --> 00:15:04.120
And a flat $5 shipping fee. That is the entire

00:15:04.120 --> 00:15:07.159
equation. No hidden implementation fees. No formula

00:15:07.159 --> 00:15:09.779
replacement kickbacks. None. If we go back to

00:15:09.779 --> 00:15:12.740
that leukemia drug in my TNIB, which was costing

00:15:12.740 --> 00:15:15.179
the patient on the high deductible plan up to

00:15:15.179 --> 00:15:17.799
$3 ,200 a month under the traditional system,

00:15:18.740 --> 00:15:21.940
what does that exact same pill cost through this

00:15:21.940 --> 00:15:24.720
transparent model? On the Cost Plus Drugs platform,

00:15:25.039 --> 00:15:27.620
that exact same one -month supply of imatinib

00:15:27.620 --> 00:15:33.039
costs between $13 .40 and $35 .10. $13 instead

00:15:33.039 --> 00:15:35.220
of $3 ,000. You are looking at a savings of well

00:15:35.220 --> 00:15:38.559
over 90%. The financial toxicity is completely

00:15:38.559 --> 00:15:40.600
removed from the equation. Entirely. And their

00:15:40.600 --> 00:15:43.600
ability to scale this model has been really significant.

00:15:43.980 --> 00:15:47.279
They launched with roughly 100 essential medications.

00:15:47.539 --> 00:15:49.879
And they grew very fast. They quickly scale to

00:15:49.879 --> 00:15:52.980
over 2 ,200. And today, they carry over 2 ,500

00:15:52.980 --> 00:15:55.240
different medications. They cover almost everything.

00:15:55.320 --> 00:15:57.220
Right, from cardiovascular health and infections

00:15:57.220 --> 00:16:01.220
diseases to oncology and dermatology. The data

00:16:01.220 --> 00:16:04.179
in dermatology is particularly striking in the

00:16:04.179 --> 00:16:07.460
reports. Yes. A recent analysis showed that MCC

00:16:07.460 --> 00:16:12.820
PDC costs average roughly $17 for certain common

00:16:12.820 --> 00:16:15.000
dermatology prospections. And if you compare

00:16:15.000 --> 00:16:18.600
that to traditional discount. coupon platforms.

00:16:18.720 --> 00:16:21.019
Or ones that still rely on the convoluted PDM

00:16:21.019 --> 00:16:23.379
network to generate their prices. The average

00:16:23.379 --> 00:16:26.279
cost there was over $31. Almost double the cost,

00:16:26.419 --> 00:16:29.019
even with a discount coupon. Exactly. But it

00:16:29.019 --> 00:16:31.679
isn't just a handful of anecdotes or cherry -picked

00:16:31.679 --> 00:16:34.320
generic price drops. The academic community is

00:16:34.320 --> 00:16:36.720
actively auditing this model to see if it holds

00:16:36.720 --> 00:16:40.059
up at scale. Yes. There was a major study published

00:16:40.059 --> 00:16:43.000
recently in JAMA Network Open that really dug

00:16:43.000 --> 00:16:45.720
into the math on a systemic level. JAMA is about

00:16:45.720 --> 00:16:48.259
as rigorous as it gets. They look at a specific

00:16:48.259 --> 00:16:50.980
cohort of medications to see how the transparent

00:16:50.980 --> 00:16:54.000
cash model stacked up against heavily negotiated

00:16:54.000 --> 00:16:57.259
commercial insurance rates. What did the researchers

00:16:57.259 --> 00:16:59.840
actually find when they ran the numbers? The

00:16:59.840 --> 00:17:02.720
JAMA Network Open Study is a crucial piece of

00:17:02.720 --> 00:17:05.319
validation for the model. The researchers analyzed

00:17:05.319 --> 00:17:08.720
33 different neurological medications. Neurological

00:17:08.720 --> 00:17:10.579
drugs are often chronic maintenance medications,

00:17:10.779 --> 00:17:13.369
right? Exactly. Things for seizure disorders,

00:17:13.650 --> 00:17:16.910
Parkinson's, or severe migraines. So the cumulative

00:17:16.910 --> 00:17:19.690
cost burden for these patients is naturally very

00:17:19.690 --> 00:17:22.329
high. So they compare the costs paid by third

00:17:22.329 --> 00:17:24.890
-party commercial insurance plans, which utilize

00:17:24.890 --> 00:17:27.769
PBMs, against the cash prices paid by patients

00:17:27.769 --> 00:17:30.329
using cost -plus drugs. Right. And the primary

00:17:30.329 --> 00:17:33.470
finding was that MCCTDC consistently delivered

00:17:33.470 --> 00:17:36.109
lower total system costs across the board. Lower

00:17:36.109 --> 00:17:38.470
total system costs? Yes. The fundamental cost

00:17:38.470 --> 00:17:40.849
of acquiring and dispensing the drug was consi—

00:17:40.490 --> 00:17:43.470
cheaper without the middleman extraction. Total

00:17:43.470 --> 00:17:45.970
system cost is a vital concept for us to highlight

00:17:45.970 --> 00:17:48.390
here. That means the patient's out -of -pocket

00:17:48.390 --> 00:17:51.289
cost at the pharmacy counter, combined with whatever

00:17:51.289 --> 00:17:53.950
massive balance the insurance plan paid behind

00:17:53.950 --> 00:17:57.089
the scenes. It is the actual true cost of the

00:17:57.089 --> 00:17:59.250
drug to society. But here's where it gets really

00:17:59.250 --> 00:18:02.690
interesting. The YAMA study revealed a bizarre,

00:18:03.289 --> 00:18:05.450
almost counterintuitive paradox in the data.

00:18:05.650 --> 00:18:07.839
The paradox is fascinating. For some of these

00:18:07.839 --> 00:18:10.500
neurological medications, patients who actually

00:18:10.500 --> 00:18:13.700
had Good commercial insurance paid more out of

00:18:13.700 --> 00:18:15.920
pocket using the cheap transparent cost plus

00:18:15.920 --> 00:18:17.640
model than they would have if they just went

00:18:17.640 --> 00:18:19.599
to their local pharmacy and use their traditional

00:18:19.599 --> 00:18:22.079
insurance copay. It seems completely backward

00:18:22.079 --> 00:18:24.119
at first glance. The researchers noted that it

00:18:24.119 --> 00:18:26.980
was difficult to pinpoint exactly why the direct

00:18:26.980 --> 00:18:29.680
to consumer model achieves lower total costs

00:18:29.680 --> 00:18:32.279
for the system, but sometimes resulted in higher

00:18:32.279 --> 00:18:35.319
immediate out of pocket costs for insured individuals.

00:18:35.599 --> 00:18:37.859
Why does that happen? It seems paradoxical until

00:18:37.859 --> 00:18:40.220
you understand the psychology of benefit design.

00:18:40.200 --> 00:18:43.279
psychology of it. Yes. Traditional insurance

00:18:43.279 --> 00:18:46.140
plans subsidize the immediate cost for the end

00:18:46.140 --> 00:18:49.140
user at the pharmacy counter. They do this to

00:18:49.140 --> 00:18:51.500
insulate the patient from the true cost of the

00:18:51.500 --> 00:18:53.319
system. OK, let's walk through an example of

00:18:53.319 --> 00:18:55.960
that. Let's say a drug has a massively inflated

00:18:55.960 --> 00:19:00.160
list price of $400. The PBM negotiates it down

00:19:00.160 --> 00:19:03.700
to $200, keeps $50, and bills the health plan

00:19:03.700 --> 00:19:08.019
$150. OK, so the health plan is at $150. Right.

00:19:08.279 --> 00:19:10.700
But the health plan allows the patient to pick

00:19:10.640 --> 00:19:14.339
up the drug for a flat $10 copay. So the patient

00:19:14.339 --> 00:19:17.400
feels great. They got a $400 drug for $10. Exactly.

00:19:17.980 --> 00:19:21.079
Meanwhile, the system is bleeding capital, driving

00:19:21.079 --> 00:19:23.900
up everyone's monthly premiums year over year

00:19:23.900 --> 00:19:27.740
just to cover that hidden $150 charge. But the

00:19:27.740 --> 00:19:29.440
patient doesn't see that on Tuesday when they

00:19:29.440 --> 00:19:31.460
pick up the pill. They never see it. Now the

00:19:31.460 --> 00:19:33.720
Cost Plus model might acquire that exact same

00:19:33.720 --> 00:19:36.099
drug and sell it for a transparent flat rate

00:19:36.099 --> 00:19:39.559
of $15 total. So the total system cost drops

00:19:39.559 --> 00:19:43.480
from $150 to $15. That is a massive win for society.

00:19:43.819 --> 00:19:46.680
It is. But to the individual patient standing

00:19:46.680 --> 00:19:49.799
at the counter, their choice is either a $10

00:19:49.799 --> 00:19:53.759
copay with their insurance card or a $15 cash

00:19:53.759 --> 00:19:56.789
payment at Cost Plus. So the patient is essentially

00:19:56.789 --> 00:20:00.009
asked to act against their own immediate financial

00:20:00.009 --> 00:20:02.509
interest for the greater good of the overall

00:20:02.509 --> 00:20:05.750
system, which is a very hard sell. If my copay

00:20:05.750 --> 00:20:09.559
is $10. I am going to use my copay. I am not

00:20:09.559 --> 00:20:13.180
going to voluntarily pay $15 cash just to save

00:20:13.180 --> 00:20:16.220
my giant insurance company $150 in the background.

00:20:16.900 --> 00:20:19.460
Exactly. It asks the consumer to bear the friction

00:20:19.460 --> 00:20:21.980
of systemic reform. That is a tough hurdle. It

00:20:21.980 --> 00:20:24.079
is exactly the friction we are seeing play out.

00:20:24.420 --> 00:20:26.940
The individual patient feels insulated at the

00:20:26.940 --> 00:20:29.859
exact moment of purchase. If they prioritize

00:20:29.859 --> 00:20:32.099
their immediate subsidized copay over the macro

00:20:32.099 --> 00:20:34.380
health of the health care system, the transparent

00:20:34.380 --> 00:20:36.819
model really struggles to capture that insu—

00:20:36.400 --> 00:20:39.019
volume. Why would I pay more out of pocket even

00:20:39.019 --> 00:20:41.220
if my insurance company is being completely gouged

00:20:41.220 --> 00:20:43.519
in the background? The traditional system relies

00:20:43.519 --> 00:20:46.220
heavily on that apathy. It relies on the patient

00:20:46.220 --> 00:20:48.599
not caring what the drug actually costs to the

00:20:48.599 --> 00:20:52.220
system as long as their specific individual copay

00:20:52.220 --> 00:20:55.000
is low. Overcoming that psychological hurdle

00:20:55.000 --> 00:20:57.700
is the biggest challenge for the cost plus model

00:20:57.700 --> 00:21:00.460
in the insured market. Without a doubt. And there

00:21:00.460 --> 00:21:02.980
is another massive limitation to the direct -to

00:21:02.980 --> 00:21:06.960
-consumer mail order model. Mail order is fantastic

00:21:06.960 --> 00:21:09.680
for chronic maintenance medications. If you take

00:21:09.680 --> 00:21:12.259
a statin for your cholesterol every single day,

00:21:12.640 --> 00:21:15.180
getting a 90 -day supply in the mail works perfectly.

00:21:15.559 --> 00:21:17.599
But healthcare is often acute and immediate.

00:21:18.079 --> 00:21:20.579
If you wake up and your child has a raging fever

00:21:20.579 --> 00:21:23.279
and strep throat, you cannot log onto a website.

00:21:23.559 --> 00:21:26.019
request a prescription transfer, and wait three

00:21:26.019 --> 00:21:28.180
to five business days for an antibiotic to arrive

00:21:28.180 --> 00:21:30.259
in the mail. You need that amoxicillin right

00:21:30.259 --> 00:21:33.240
now, today. The internet cannot solve acute physical

00:21:33.240 --> 00:21:36.039
illness. Yeah. So Cos Plus drugs had to evolve.

00:21:36.200 --> 00:21:37.839
They had to figure out a way to step out of the

00:21:37.839 --> 00:21:40.039
digital space and integrate into the physical

00:21:40.039 --> 00:21:42.000
brick and mortar world. Which brings us to their

00:21:42.000 --> 00:21:44.579
physical retail alliances and the rollout of

00:21:44.579 --> 00:21:47.190
the Team Cuban card. This is a really necessary

00:21:47.190 --> 00:21:50.029
evolution. It was. It started as a relatively

00:21:50.029 --> 00:21:53.210
contained pilot program specifically for employees

00:21:53.210 --> 00:21:55.569
of the Dallas Mavericks and the various Mark

00:21:55.569 --> 00:21:57.710
Cuban companies. They just wanted to test the

00:21:57.710 --> 00:22:00.150
waters. They wanted to test if they could actually

00:22:00.150 --> 00:22:03.750
bring transparent pricing to a physical register.

00:22:04.210 --> 00:22:07.410
And it worked. And it has since expanded massively.

00:22:07.490 --> 00:22:09.619
How massive are we talking? Patients can now

00:22:09.619 --> 00:22:12.380
present their Team Cuban card, which functions

00:22:12.380 --> 00:22:14.920
essentially like a transparent benefit card at

00:22:14.920 --> 00:22:18.240
over 17 ,000 participating pharmacies across

00:22:18.240 --> 00:22:20.839
the country. 17 ,000. That isn't just a niche

00:22:20.839 --> 00:22:23.460
network of small mom and pop shops. No, it includes

00:22:23.460 --> 00:22:27.180
massive national grocery chains, Kroger Albertsons,

00:22:27.420 --> 00:22:30.180
Meijer Publix, and Food Lion operating right

00:22:30.180 --> 00:22:32.640
alongside independent community pharmacies. So

00:22:32.640 --> 00:22:34.720
they are building a parallel network within the

00:22:34.720 --> 00:22:36.940
existing infrastructure. A parallel transparent

00:22:36.940 --> 00:22:39.509
network. But if they're using the physical retail

00:22:39.509 --> 00:22:42.890
space, they can't just charge a flat $5 shipping

00:22:42.890 --> 00:22:45.849
and $5 labor fee like they do online. No, the

00:22:45.849 --> 00:22:48.309
economics are totally different. Right. Running

00:22:48.309 --> 00:22:51.470
a massive grocery store pharmacy or an independent

00:22:51.470 --> 00:22:54.890
shop is vastly different than running a centralized

00:22:54.890 --> 00:22:58.180
mail order warehouse. How does the transparent

00:22:58.180 --> 00:23:01.279
cost plus math adapt to the physical register?

00:23:01.619 --> 00:23:04.660
The pricing model maintains its absolute transparency,

00:23:05.039 --> 00:23:07.619
but the variables adjust to reflect the reality

00:23:07.619 --> 00:23:09.940
of retail overhead. Okay, walk us through the

00:23:09.940 --> 00:23:12.720
new variables. If a patient walks into an affiliate

00:23:12.720 --> 00:23:15.160
pharmacy and hands over the Team Cuban card,

00:23:15.660 --> 00:23:18.779
The pricing structure is calculated precisely.

00:23:19.279 --> 00:23:22.000
It is the wholesale acquisition cost of the drug

00:23:22.000 --> 00:23:26.019
plus that standard 15 % markup for cost plus.

00:23:26.039 --> 00:23:28.900
Okay, that part is the same. Plus a flat $12

00:23:28.900 --> 00:23:31.480
baseline dispensing fee that goes entirely and

00:23:31.480 --> 00:23:33.880
directly to the physical pharmacy. $12 straight

00:23:33.880 --> 00:23:36.900
to the pharmacy. Yes. Plus a $1 processing fee

00:23:36.900 --> 00:23:39.440
to run the network transaction. Let's break that

00:23:39.440 --> 00:23:41.420
down with a real -world example from the retail

00:23:41.420 --> 00:23:43.799
data. Let's look at fluoxetine. Say a patient

00:23:43.799 --> 00:23:47.799
needs 30 capsules of 20mg Flooxetine, which is

00:23:47.799 --> 00:23:50.200
the generic equivalent of Prozac. The acquisition

00:23:50.200 --> 00:23:53.380
cost on the wholesale market is $0 .57. The 15

00:23:53.380 --> 00:23:56.559
% markup on that $0 .57 is roughly $0 .08. And

00:23:56.559 --> 00:23:59.200
then you add the $12 dispensing fee for the pharmacist

00:23:59.200 --> 00:24:01.539
and the $1 processing fee. The total cost to

00:24:01.539 --> 00:24:04.599
the patient at the register is exactly $13 .65.

00:24:05.079 --> 00:24:08.279
That $12 dispensing fee seems like the absolute

00:24:08.279 --> 00:24:10.859
linchpin of this entire physical strategy. It

00:24:10.859 --> 00:24:14.359
is the entire ballgame for retail. For decades.

00:24:14.250 --> 00:24:17.450
independent pharmacies have been screaming that

00:24:17.450 --> 00:24:20.930
PBMs reimburse them at rates that literally force

00:24:20.930 --> 00:24:23.329
them to lose money on every prescription they

00:24:23.329 --> 00:24:25.549
fill. They are dealing with retroactive clawbacks

00:24:25.549 --> 00:24:28.269
constantly. Right. Those are called DIR fees

00:24:28.269 --> 00:24:32.470
or direct and indirect remuneration fees, where

00:24:32.470 --> 00:24:35.009
a PBM will just randomly extract money from the

00:24:35.009 --> 00:24:37.890
pharmacy months after a drug was dispensed. Just

00:24:37.890 --> 00:24:40.450
crushing their margins. How does a guaranteed

00:24:40.450 --> 00:24:44.049
$12 fee change the survival calculus? for an

00:24:44.049 --> 00:24:46.289
independent pharmacist. It is literally the difference

00:24:46.289 --> 00:24:48.369
between keeping the lights on and closing the

00:24:48.369 --> 00:24:50.829
doors forever. Give us some precise context on

00:24:50.829 --> 00:24:53.410
that. Let's look at the operational reality for

00:24:53.410 --> 00:24:56.750
an independent owner. Take Tara Schneider. She's

00:24:56.750 --> 00:24:59.109
a pharmacist who owns and operates Middletown

00:24:59.109 --> 00:25:02.109
Pharmacy in Kentucky. She provided an analysis

00:25:02.109 --> 00:25:05.289
of her profit margins under traditional PBM contracts

00:25:05.289 --> 00:25:07.809
versus this transparent model. What did the numbers

00:25:07.809 --> 00:25:10.849
show? She pointed out that when she fills a standard

00:25:10.849 --> 00:25:14.410
30 -day supply of the generic acid reflux drug

00:25:14.410 --> 00:25:17.529
Pantoprazole under a traditional major commercial

00:25:17.529 --> 00:25:20.569
insurance plan like UnitedHealthcare, Her pharmacy

00:25:20.569 --> 00:25:26.490
nets a profit of exactly $1 .38. $1 .38. To stock

00:25:26.490 --> 00:25:29.410
the drug consult with the patient, process the

00:25:29.410 --> 00:25:32.250
complex insurance claim, and dispense the medication

00:25:32.250 --> 00:25:36.069
safely. Yes. Compare that $1 .38 to the guaranteed

00:25:36.069 --> 00:25:38.890
un -clawable $12 she makes under the Team Cuban

00:25:38.890 --> 00:25:41.069
card. That is a night and day difference. Furthermore,

00:25:41.150 --> 00:25:44.009
for cold chain drugs that require heavy refrigeration

00:25:44.009 --> 00:25:47.250
or drugs with complex FDA risk evaluation and

00:25:47.250 --> 00:25:50.019
mitigation strategies known as REMAS. Drugs that

00:25:50.019 --> 00:25:52.799
require extensive pharmacist monitoring. Exactly.

00:25:53.039 --> 00:25:55.900
For those complex drugs, the fee goes up to $14.

00:25:57.099 --> 00:25:59.640
PBMs have been squeezing independent pharmacies

00:25:59.640 --> 00:26:02.400
to the point of bankruptcy, creating massive

00:26:02.400 --> 00:26:05.039
pharmacy deserts in rural and low -income areas.

00:26:05.299 --> 00:26:08.519
And this transparent flat fee model offers them

00:26:08.519 --> 00:26:11.619
a sustainable, predictable way to actually stay

00:26:11.619 --> 00:26:14.940
in business. It is a profound shift for the retail

00:26:14.940 --> 00:26:17.799
landscape. The vast majority of patients, some

00:26:17.799 --> 00:26:20.900
surveys say around 85%, still prefer getting

00:26:20.900 --> 00:26:22.740
their prescriptions from a physical brick and

00:26:22.740 --> 00:26:25.460
mortar pharmacy rather than an anonymous mail

00:26:25.460 --> 00:26:28.130
order facility. People want to establish a relationship

00:26:28.130 --> 00:26:29.869
with their pharmacist. They do. They want to

00:26:29.869 --> 00:26:31.730
be able to ask questions about drug interactions.

00:26:32.190 --> 00:26:33.970
They want immediate care when they are sick.

00:26:34.430 --> 00:26:36.950
And now this parallel network allows them to

00:26:36.950 --> 00:26:39.369
get that care without getting completely gouged.

00:26:39.509 --> 00:26:41.710
While ensuring the independent pharmacist actually

00:26:41.710 --> 00:26:44.349
makes a living wage for their clinical expertise.

00:26:44.630 --> 00:26:47.069
It feels like a massive victory. But we have

00:26:47.069 --> 00:26:49.089
to acknowledge a hard truth about the pharmaceutical

00:26:49.089 --> 00:26:52.240
market. As amazing as these savings on generic

00:26:52.240 --> 00:26:55.279
pills are, the generic market is only a fraction

00:26:55.279 --> 00:26:58.190
of the total spending. That is unfortunately

00:26:58.190 --> 00:27:02.289
very true. The real financial toxicity, the overwhelming

00:27:02.289 --> 00:27:05.289
burden that crushes health plan budgets, lies

00:27:05.289 --> 00:27:08.150
in what the industry calls specialty drugs. That

00:27:08.150 --> 00:27:10.869
is correct. While small molecule generic drugs

00:27:10.869 --> 00:27:13.970
make up over 90 % of the actual physical prescriptions

00:27:13.970 --> 00:27:16.490
filled in the United States, they account for

00:27:16.490 --> 00:27:19.009
a relatively small percentage of the total national

00:27:19.009 --> 00:27:22.759
drug spending. The real money. The billions upon

00:27:22.759 --> 00:27:25.160
billions of dollars that drive the PBM profit

00:27:25.160 --> 00:27:27.740
engines is heavily concentrated in specialty

00:27:27.740 --> 00:27:29.980
medicines. And these are not simple chemical

00:27:29.980 --> 00:27:33.000
compounds pressed into a pill. No, they're incredibly

00:27:33.000 --> 00:27:36.259
complex, often biologic drugs. Biologics are

00:27:36.259 --> 00:27:39.700
essentially large, highly complex molecules manufactured

00:27:39.700 --> 00:27:43.240
inside living systems like microorganisms or

00:27:43.240 --> 00:27:45.500
specially engineered plant or animal cell lines.

00:27:45.539 --> 00:27:47.559
They are notoriously difficult to manufacture,

00:27:47.759 --> 00:27:49.519
highly sensitive to temperature and handling.

00:27:49.849 --> 00:27:52.069
and they are used to treat severe, chronic, and

00:27:52.069 --> 00:27:54.490
complex conditions. Things like rheumatoid arthritis,

00:27:54.869 --> 00:27:57.190
severe plaque psoriasis, Crohn's disease, and

00:27:57.190 --> 00:28:00.049
various forms of cancer. And precisely because

00:28:00.049 --> 00:28:02.609
their list prices are so astronomically high,

00:28:03.150 --> 00:28:05.210
often tens or hundreds of thousands of dollars

00:28:05.210 --> 00:28:08.009
a year, they are the primary battlefield for

00:28:08.009 --> 00:28:11.430
PBM rebate negotiations. The fact that MCC PDC

00:28:11.430 --> 00:28:14.349
is now aggressively entering this highly guarded

00:28:14.349 --> 00:28:17.890
specialty space is a monumental shift in strategy.

00:28:18.089 --> 00:28:20.730
And their weapon of choice to breach this fortress

00:28:20.730 --> 00:28:23.390
is the biosimilar. The biosimilar, yes. For the

00:28:23.390 --> 00:28:26.210
listener, a biosimilar is conceptually akin to

00:28:26.210 --> 00:28:29.509
a generic version of a biologic drug. It isn't

00:28:29.509 --> 00:28:31.150
chemically identical because you are dealing

00:28:31.150 --> 00:28:33.009
with living cells. Right, you can't perfectly

00:28:33.009 --> 00:28:35.509
clone a living cell batch. But the FDA certifies

00:28:35.509 --> 00:28:38.170
that it has no clinically meaningful differences

00:28:38.170 --> 00:28:40.470
from the highly expensive original reference

00:28:40.470 --> 00:28:43.289
drug. The sources point to a massive new addition

00:28:43.289 --> 00:28:45.789
to the Cost Plus portfolio that illustrates this

00:28:45.789 --> 00:28:48.549
perfectly. They have added a drug called Stargemsa.

00:28:48.779 --> 00:28:51.680
This is a biosimilar for a massive blockbuster

00:28:51.680 --> 00:28:54.500
inflammatory drug called Stellara. Stellara has

00:28:54.500 --> 00:28:57.079
historically cost patients and health plans tens

00:28:57.079 --> 00:28:59.460
of thousands of dollars a year. It is a massive

00:28:59.460 --> 00:29:02.039
line item on any corporate health budget. What

00:29:02.039 --> 00:29:04.559
is Cost Plus Drugs listing this biosimilar for?

00:29:04.759 --> 00:29:07.140
They are completely bypassing the traditional

00:29:07.140 --> 00:29:10.420
specialty pharmacy markup. Cost Plus Drugs is

00:29:10.420 --> 00:29:14.380
listing Star Gemza at a starting price of $345

00:29:14.380 --> 00:29:17.920
per quarter for a pre -filled syringe. $345 a

00:29:17.920 --> 00:29:22.059
quarter. That represents an astonishing 99 %

00:29:22.059 --> 00:29:24.440
drop from the Reference Biologics original list

00:29:24.440 --> 00:29:27.900
price. That is insane. A 99 % drop. They are

00:29:27.900 --> 00:29:30.759
taking a drug that used to define financial toxicity

00:29:30.759 --> 00:29:34.019
for autoimmune patients and pricing it like a

00:29:34.119 --> 00:29:36.400
standard mid -tier generic. That is a staggering

00:29:36.400 --> 00:29:39.319
press collapse. But the traditional PBMs aren't

00:29:39.319 --> 00:29:41.220
just going to sit back and let their most profitable

00:29:41.220 --> 00:29:43.460
revenue streams evaporate overnight. Oh, definitely

00:29:43.460 --> 00:29:45.839
not. They control the formularies. They control

00:29:45.839 --> 00:29:48.640
what the insurance plans actually cover. If we

00:29:48.640 --> 00:29:50.599
look at how the massive incumbents are reacting

00:29:50.599 --> 00:29:53.359
to the introduction of these cheap biosimilars,

00:29:53.920 --> 00:29:56.140
it exposes a lot of the hypocrisy in the system.

00:29:56.339 --> 00:29:58.460
If we connect this to the bigger picture of corporate

00:29:58.460 --> 00:30:01.769
strategy, The launch of Stargemza exposes the

00:30:01.769 --> 00:30:03.869
deep systemic dysfunction of the traditional

00:30:03.869 --> 00:30:06.549
drug channel. Let's talk about Express Scripts.

00:30:06.890 --> 00:30:10.269
How is a giant like Express Scripts handling

00:30:10.269 --> 00:30:12.670
the formulary placement for Stellara and its

00:30:12.670 --> 00:30:16.380
biosimilars as we head into 2026? We have a detailed

00:30:16.380 --> 00:30:19.480
report from drug channels analyzing Express Scripts'

00:30:19.799 --> 00:30:22.440
national preferred formulary strategy for 2026.

00:30:22.740 --> 00:30:25.400
What are they doing? On the surface, Express

00:30:25.400 --> 00:30:27.240
Scripts is taking what looks like a positive

00:30:27.240 --> 00:30:30.160
step. They are removing the massively expensive

00:30:30.160 --> 00:30:32.519
original reference products to Lara from their

00:30:32.519 --> 00:30:35.140
preferred formulary, forcing patients toward

00:30:35.140 --> 00:30:37.200
biosimilars. Well, that sounds like a win for

00:30:37.200 --> 00:30:40.160
the system on paper. On paper, yes. But the mechanics

00:30:40.160 --> 00:30:43.119
of how they are doing it maintain a bizarre pricing

00:30:43.119 --> 00:30:44.759
double standard. What kind of double standard?

00:30:44.619 --> 00:30:47.759
They're adding cheap, deeply discounted biosimilars

00:30:47.759 --> 00:30:51.019
to the list, yes, but they are also giving preferred

00:30:51.019 --> 00:30:54.640
co -equal placement to a much higher priced private

00:30:54.640 --> 00:30:57.279
label version of the exact same biosimilar. A

00:30:57.279 --> 00:30:59.740
private label version? Yes. This higher priced

00:30:59.740 --> 00:31:02.359
version comes from a company called Qualent Pharmaceuticals,

00:31:02.480 --> 00:31:05.279
which is essentially sourcing the drug from Samsung

00:31:05.279 --> 00:31:07.380
BioAbyss. And what's the catch with Qualent?

00:31:07.549 --> 00:31:09.970
The catch is that Qualent is a private label

00:31:09.970 --> 00:31:13.490
subsidiary, heavily affiliated with the PBM ecosystem

00:31:13.490 --> 00:31:15.789
itself. OK, let me make sure I'm following the

00:31:15.789 --> 00:31:19.150
shell game here. The PBM is pushing a cheap version

00:31:19.150 --> 00:31:22.029
of the drug onto the fornillary. Right. But right

00:31:22.029 --> 00:31:24.309
next to it, they're pushing a vastly more expensive

00:31:24.309 --> 00:31:27.509
version of the exact same clinical drug produced

00:31:27.509 --> 00:31:30.450
by a company that is affiliated with the PBM's

00:31:30.450 --> 00:31:32.880
own corporate structure. That is exactly what

00:31:32.880 --> 00:31:41.690
they're doing. actively choose the higher priced

00:31:41.690 --> 00:31:44.690
biosimilar when a functionally identical cheap

00:31:44.690 --> 00:31:46.990
one is sitting right there. Because of the addiction

00:31:46.990 --> 00:31:49.289
to rebates? It always comes back to the rebates.

00:31:49.369 --> 00:31:52.130
Always. The higher priced private label biosimilar

00:31:52.130 --> 00:31:54.849
generates a massive rebate spread. The employer

00:31:54.849 --> 00:31:57.150
chooses the high list price because they know

00:31:57.150 --> 00:31:59.529
it comes with a massive rebate check at the end

00:31:59.529 --> 00:32:02.190
of the quarter. Which they use to artificially

00:32:02.190 --> 00:32:04.950
buy down their overall premium costs to make

00:32:04.950 --> 00:32:07.049
their benefits package look more attractive to

00:32:07.049 --> 00:32:10.779
employees. Exactly. And the PBM happily facilitates

00:32:10.779 --> 00:32:13.160
this because they take a cut of that massive

00:32:13.160 --> 00:32:15.700
rebate as it flows through their hands. It's

00:32:15.700 --> 00:32:18.099
just moving money in circles. As the prominent

00:32:18.099 --> 00:32:20.660
industry analyst Adam Fain noted in our research

00:32:20.660 --> 00:32:23.359
stack, employer plan sponsors suffer from an

00:32:23.359 --> 00:32:26.619
unrequited love of rebates over lower true prices.

00:32:26.799 --> 00:32:29.519
An unrequited love of rebates. That is a brutal

00:32:29.519 --> 00:32:31.259
assessment. It is accurate, though. They are

00:32:31.259 --> 00:32:33.720
completely addicted to the cash flow of the rebate

00:32:33.720 --> 00:32:36.519
check. They prioritize that cash flow even if

00:32:36.519 --> 00:32:39.359
it means that sickest employees are forced to

00:32:39.359 --> 00:32:42.200
pay heavily inflated co -insurance out of pocket

00:32:42.200 --> 00:32:44.559
based on the higher list price of the private

00:32:44.559 --> 00:32:47.259
label drug. It is a financial shell game that

00:32:47.259 --> 00:32:49.900
prioritizes corporate balance sheets over patient

00:32:49.900 --> 00:32:53.319
affordability every single time. And MCC PDC's

00:32:53.319 --> 00:32:55.680
entry into the specialty market with a flat non

00:32:55.680 --> 00:32:59.819
-negotiable $345 price tag fundamentally threatens

00:32:59.819 --> 00:33:02.200
this entire shell game. Because it forcefully

00:33:02.200 --> 00:33:04.819
exposes to the public exactly what the drug actually

00:33:04.819 --> 00:33:07.710
costs to manufacture and distribute without the

00:33:07.710 --> 00:33:10.309
rebate inflation. It strips away all the plausible

00:33:10.309 --> 00:33:13.630
deniability. It is incredible how deep the dysfunction

00:33:13.630 --> 00:33:17.029
goes and how complicit the employers are in maintaining

00:33:17.029 --> 00:33:19.289
it just to get a discount on their premiums.

00:33:19.410 --> 00:33:22.829
It's systemic. But pricing manipulation and formulary

00:33:22.829 --> 00:33:26.009
games are only one side of the coin. The other

00:33:26.009 --> 00:33:28.990
side, the side that is arguably much more terrifying

00:33:28.990 --> 00:33:31.769
on a physical level, is actual availability.

00:33:32.049 --> 00:33:34.609
The physical supply chain. Because right now,

00:33:34.839 --> 00:33:37.200
The United States is dealing with a catastrophic

00:33:37.200 --> 00:33:41.140
ongoing physical supply chain crisis. We are

00:33:41.140 --> 00:33:43.680
literally running out of basic foundational drugs.

00:33:43.819 --> 00:33:46.140
The shortage numbers are alarming. As of the

00:33:46.140 --> 00:33:48.269
time these analyses were published. There are

00:33:48.269 --> 00:33:50.930
roughly 200 different drugs in active shortage

00:33:50.930 --> 00:33:54.029
across the U .S. 200. And we aren't talking about

00:33:54.029 --> 00:33:56.390
rare experimental new therapies that are hard

00:33:56.390 --> 00:33:58.690
to make. We're talking about critical decades

00:33:58.690 --> 00:34:01.569
old life saving generic medications. Hospitals

00:34:01.569 --> 00:34:03.589
are running out of albuterol for acute asthma

00:34:03.589 --> 00:34:06.289
attacks. They are rationing pediatric chemotherapies

00:34:06.289 --> 00:34:09.230
for children with cancer. How is it possible

00:34:09.230 --> 00:34:11.449
that the wealthiest country in the history of

00:34:11.449 --> 00:34:14.230
human civilization cannot keep basic 60 year

00:34:14.230 --> 00:34:16.730
old medicines on the shelf? The root cause of

00:34:16.730 --> 00:34:19.690
these physical shortages is complex, but the

00:34:19.690 --> 00:34:22.230
essential underlying dynamic is a fundamentally

00:34:22.230 --> 00:34:24.929
dysfunctional market for the physical distribution

00:34:24.929 --> 00:34:27.170
of pharmaceuticals. We just spent a lot of time

00:34:27.170 --> 00:34:30.809
talking about how PBMs control the pricing and

00:34:30.809 --> 00:34:33.210
insurance side. But when it comes to the physical

00:34:33.210 --> 00:34:36.610
purchasing and movement of generic drugs, the

00:34:36.610 --> 00:34:38.690
market is controlled by a massive bottleneck.

00:34:38.769 --> 00:34:41.590
What kind of bottleneck? Just three major wholesaler

00:34:41.590 --> 00:34:44.150
sourcing programs dominate the entire landscape.

00:34:44.329 --> 00:34:47.250
Three. Together, these three centralized purchasing

00:34:47.250 --> 00:34:50.650
entities account for approximately 90 % of all

00:34:50.650 --> 00:34:53.170
generic pharmaceutical purchases from manufacturers

00:34:53.170 --> 00:34:56.389
in the U .S. 90 % controlled by just three entities.

00:34:56.710 --> 00:34:59.289
That is an extreme bottleneck. It is essentially

00:34:59.289 --> 00:35:01.849
an oligopsiny. When you have that much concentrated

00:35:01.849 --> 00:35:05.230
buying power, you completely dictate the terms

00:35:05.230 --> 00:35:08.210
of survival for the manufacturers. How does that

00:35:08.210 --> 00:35:10.409
consolidation directly lead to empty shelves

00:35:10.409 --> 00:35:12.829
in a hospital? Because generic drugs are viewed

00:35:12.829 --> 00:35:16.050
by these wholesalers entirely as undifferentiated

00:35:16.050 --> 00:35:18.210
commodity products. They don't care about brand

00:35:18.210 --> 00:35:20.469
loyalty. They don't care about brand loyalty.

00:35:20.809 --> 00:35:22.969
They care about the absolute lowest fraction

00:35:22.969 --> 00:35:25.949
of a cent per pill. So how do they negotiate?

00:35:26.289 --> 00:35:29.309
These massive wholesalers generally utilize group

00:35:29.309 --> 00:35:32.050
purchasing organizations or GPOs to negotiate.

00:35:32.610 --> 00:35:35.409
They will issue a contract for a specific generic

00:35:35.409 --> 00:35:38.349
drug and they almost universally award that massive

00:35:38.349 --> 00:35:41.769
exclusive contract to a single primary provider.

00:35:41.909 --> 00:35:43.969
The lowest bidder. The absolute lowest bidder.

00:35:44.309 --> 00:35:47.409
This creates a relentless, ruthless race to the

00:35:47.409 --> 00:35:50.010
bottom on price. To win the contract and survive,

00:35:50.090 --> 00:35:53.530
generic manufacturers have to slash every conceivable

00:35:53.530 --> 00:35:55.969
operational cost. They offshore their manufacturing

00:35:55.969 --> 00:35:58.210
to countries with vastly cheaper labor pools

00:35:58.210 --> 00:36:00.789
and looser environmental and regulatory oversight.

00:36:01.030 --> 00:36:03.230
And they eliminate any redundant manufacturing

00:36:03.230 --> 00:36:06.019
lines. There is no backup factory. None. They

00:36:06.019 --> 00:36:08.659
run their primary facilities at absolute maximum

00:36:08.659 --> 00:36:11.619
capacity 24 hours a day with zero margin for

00:36:11.619 --> 00:36:14.079
error. So the supply chain becomes incredibly

00:36:14.079 --> 00:36:17.480
brittle and hyper extended. If you rely entirely

00:36:17.480 --> 00:36:20.239
on a single factory running at maximum capacity

00:36:20.239 --> 00:36:23.579
halfway across the world, what happens when reality

00:36:23.579 --> 00:36:26.500
strikes? If a factory in India or China discovers

00:36:26.500 --> 00:36:28.760
a bacterial contamination in a clean room or

00:36:28.760 --> 00:36:31.940
a hurricane hits a major shipping port or there

00:36:31.940 --> 00:36:34.610
is a sudden geopolitical trade dispute. The whole

00:36:34.610 --> 00:36:37.849
US supply chain for that specific drug just instantly

00:36:37.849 --> 00:36:40.670
collapses. There is no slack in the system to

00:36:40.670 --> 00:36:43.329
absorb the shock. The vulnerability is staggering.

00:36:43.530 --> 00:36:47.210
Industry data indicates that a massive 72 percent

00:36:47.210 --> 00:36:49.829
of all the active pharmaceutical ingredient or

00:36:49.829 --> 00:36:52.610
API suppliers for the U .S. market are located

00:36:52.610 --> 00:36:55.489
overseas. The API is the actual chemical compound

00:36:55.489 --> 00:36:57.429
that makes the drug work. We don't even make

00:36:57.429 --> 00:37:00.030
the raw ingredients here anymore. When a single

00:37:00.030 --> 00:37:02.369
overseas supply line goes down due to a failed

00:37:02.369 --> 00:37:05.110
FDA inspection or a localized disruption, it

00:37:05.110 --> 00:37:07.289
can take a year or more for a new manufacturing

00:37:07.289 --> 00:37:09.530
line to be approved, validated and established

00:37:09.530 --> 00:37:12.150
to address the shortfall. And the human cost

00:37:12.150 --> 00:37:15.519
of this is severe. The rates of morbidity and

00:37:15.519 --> 00:37:17.739
mortality for certain pediatric cancers in the

00:37:17.739 --> 00:37:20.199
U .S. have actually gone up in recent years simply

00:37:20.199 --> 00:37:22.960
because the baseline generic medications necessary

00:37:22.960 --> 00:37:25.659
to treat them are physically unavailable. The

00:37:25.659 --> 00:37:28.460
system has optimized for chippedness at the absolute

00:37:28.460 --> 00:37:32.199
expense of resilience. MCC PDC, by contrast,

00:37:32.320 --> 00:37:35.119
is trying to build a resilient model. They currently

00:37:35.119 --> 00:37:39.199
source roughly 40 % of their APIs from strong,

00:37:39.380 --> 00:37:41.920
highly regulated jurisdictions. Compared to the

00:37:41.920 --> 00:37:45.159
broader industry average of just 10%. But simply

00:37:45.159 --> 00:37:47.659
sourcing better ingredients from reliable allies

00:37:47.659 --> 00:37:50.480
isn't enough to solve the physical shortage problem.

00:37:50.619 --> 00:37:53.039
Right. So what does this all mean? It means we

00:37:53.039 --> 00:37:55.739
have to stop relying entirely on vulnerable global

00:37:55.739 --> 00:37:57.940
networks for our most critical survival tools.

00:37:58.079 --> 00:37:59.840
We have to start building our own factories again.

00:37:59.940 --> 00:38:01.760
We have to bring the manufacturing back home.

00:38:01.880 --> 00:38:04.239
And that leads us to the most physical, tangible

00:38:04.239 --> 00:38:06.880
part of this entire market transformation, the

00:38:06.880 --> 00:38:09.420
massive return of American pharmaceutical manufacturing.

00:38:09.639 --> 00:38:11.480
And specifically, the tip of the spear in this

00:38:11.480 --> 00:38:16.190
movement is MCC PDC's Dallas pilot plant. MCC

00:38:16.190 --> 00:38:19.750
PDC recognized very early on that relying on

00:38:19.750 --> 00:38:22.789
vulnerable offshore supply chains fundamentally

00:38:22.789 --> 00:38:25.010
contradicted their core mission of reliable,

00:38:25.110 --> 00:38:27.690
affordable access. You cannot guarantee a transparent

00:38:27.690 --> 00:38:29.510
price if you don't actually have the drug to

00:38:29.510 --> 00:38:32.050
sell. So they made a massive capital expenditure.

00:38:32.329 --> 00:38:37.510
They built an $11 million, $22 ,600 square foot

00:38:37.510 --> 00:38:40.530
advanced manufacturing plant right in the middle

00:38:40.530 --> 00:38:43.329
of the deep Elam neighborhood of Dallas, Texas.

00:38:43.570 --> 00:38:45.760
But this is not your trad— additional sprawling

00:38:45.760 --> 00:38:48.730
pharmaceutical factory churning out. billions

00:38:48.730 --> 00:38:51.730
of oral tablets in massive vats. No, the Dallas

00:38:51.730 --> 00:38:54.389
facility is highly specialized and incredibly

00:38:54.389 --> 00:38:57.750
modern. It focuses exclusively on sterile fill

00:38:57.750 --> 00:39:00.329
-finish injectables. These are the specific types

00:39:00.329 --> 00:39:02.250
of medications that are most frequently landing

00:39:02.250 --> 00:39:04.849
on the FDA shortage list. We are talking about

00:39:04.849 --> 00:39:07.650
critical emergency drugs, things like epinephrine

00:39:07.650 --> 00:39:10.489
for severe allergic reactions. And norepinephrine,

00:39:10.510 --> 00:39:12.650
which is absolutely vital for maintaining blood

00:39:12.650 --> 00:39:14.829
pressure in patients suffering from severe shock

00:39:14.829 --> 00:39:16.769
in the ICU. When you look at the descriptions

00:39:16.769 --> 00:39:18.699
of this facility, It sounds like something out

00:39:18.699 --> 00:39:21.429
of a science fiction movie. The outside blends

00:39:21.429 --> 00:39:24.449
right into the deep LM arts district. It has

00:39:24.449 --> 00:39:27.710
this vibrant massive mural featuring a pegasus

00:39:27.710 --> 00:39:30.489
intertwined with DNA strands. But inside it is

00:39:30.489 --> 00:39:32.969
a master class in modern engineering. You don't

00:39:32.969 --> 00:39:36.050
see massive open vats or technicians in standard

00:39:36.050 --> 00:39:39.710
lab coats. You see incredible stainless steel

00:39:39.710 --> 00:39:42.909
water for injection generation systems, miles

00:39:42.909 --> 00:39:46.030
of pristine perfectly welded piping, and these

00:39:46.030 --> 00:39:49.230
incredibly advanced VanRX robotic fill finished

00:39:49.260 --> 00:39:53.079
systems operating completely inside sealed sterile

00:39:53.079 --> 00:39:55.659
glass enclosures. The robotic technology is what

00:39:55.659 --> 00:39:58.719
makes this plant truly revolutionary. It completely

00:39:58.719 --> 00:40:01.039
removes the human element from the sterile environment,

00:40:01.260 --> 00:40:03.739
which drastically reduces the risk of contamination.

00:40:03.960 --> 00:40:06.219
The facility utilizes single -use disposable

00:40:06.219 --> 00:40:08.079
components, meaning they don't have to spend

00:40:08.079 --> 00:40:10.480
days scrubbing and sterilizing permanent steel

00:40:10.480 --> 00:40:13.139
pipes between drug runs. They use robotic arms

00:40:13.139 --> 00:40:16.179
to handle the vials and AI machine vision systems

00:40:16.179 --> 00:40:18.599
to monitor product quality and particulate matter.

00:40:18.480 --> 00:40:30.619
in real time. You have to shut the entire system

00:40:30.619 --> 00:40:33.880
down, perform exhaustive cleaning, scurrilize

00:40:33.880 --> 00:40:36.739
the equipment run validation batches, and often

00:40:36.739 --> 00:40:39.820
wait for new regulatory sign -offs. The advanced

00:40:39.820 --> 00:40:41.980
robotic systems in the Dallas plant are designed

00:40:41.980 --> 00:40:45.440
for hyperagility. They can pivot the entire manufacturing

00:40:45.440 --> 00:40:48.320
line to address a sudden national drug shortage

00:40:48.320 --> 00:40:52.260
in just four hours. Four hours. That is mind

00:40:52.260 --> 00:40:54.559
-blowing agility. A hospital could announce they

00:40:54.559 --> 00:40:56.699
are out of emergency epinephrine on a Tuesday

00:40:56.699 --> 00:40:59.639
morning, and by Tuesday afternoon a factory in

00:40:59.639 --> 00:41:01.699
Texas is already spinning up a line to replace

00:41:01.699 --> 00:41:03.940
it. How is that even possible from a regulatory

00:41:03.940 --> 00:41:06.260
standpoint? Doesn't the FDA require mountains

00:41:06.260 --> 00:41:08.400
of paperwork before you can just switch production?

00:41:08.880 --> 00:41:11.440
They achieve this unprecedented speed partly

00:41:11.440 --> 00:41:14.099
through the robotic technology but equally through

00:41:14.099 --> 00:41:16.800
a very specific regulatory strategy. The Dallas

00:41:16.800 --> 00:41:19.420
facility operates under a special FDA designation

00:41:19.420 --> 00:41:22.940
known as a 503b outsourcing compounding site.

00:41:23.159 --> 00:41:24.800
What does that designation allow them to do?

00:41:24.960 --> 00:41:27.679
This designation was created under the Drug Quality

00:41:27.679 --> 00:41:30.960
and Security Act to bridge the gap between small

00:41:30.960 --> 00:41:34.179
-time neighborhood compounding pharmacies and

00:41:34.179 --> 00:41:43.110
massive, rigid drug manufacturers. large batches

00:41:43.110 --> 00:41:45.829
of drugs that are currently listed on the FDA's

00:41:45.829 --> 00:41:47.829
official shortage list. Without having to go

00:41:47.829 --> 00:41:50.349
through the years -long traditional new drug

00:41:50.349 --> 00:41:52.789
application process for every single batch. It

00:41:52.789 --> 00:41:55.409
gives them the legal flexibility to rapidly pivot

00:41:55.409 --> 00:41:57.550
and manufacture whatever the market desperately

00:41:57.550 --> 00:41:59.690
needs that week. While still maintaining full

00:41:59.690 --> 00:42:02.469
compliance with strict current good manufacturing

00:42:02.469 --> 00:42:05.110
practices. Right now the pilot facility's capacity

00:42:05.110 --> 00:42:08.429
is estimated at roughly one to two million sterile

00:42:08.429 --> 00:42:11.769
doses a year. That is enough volume to completely

00:42:11.769 --> 00:42:15.070
alleviate acute shortages for four or five large

00:42:15.070 --> 00:42:17.269
regional hospital systems. But they view this

00:42:17.269 --> 00:42:19.690
as just a proof of concept. They already drafted

00:42:19.690 --> 00:42:22.650
blueprints for a massive $300 million expansion

00:42:22.650 --> 00:42:25.650
facility capable of producing over 100 million

00:42:25.650 --> 00:42:28.989
sterile units annually. A facility of that monumental

00:42:28.989 --> 00:42:31.489
scale could theoretically alleviate the majority

00:42:31.489 --> 00:42:34.489
of acute sterile drug shortages across the entire

00:42:34.489 --> 00:42:37.670
United States. But to build a $300 million mega

00:42:37.670 --> 00:42:41.920
plant? you need massive capital injection. And

00:42:41.920 --> 00:42:44.599
you need the broader regulatory environment to

00:42:44.599 --> 00:42:46.760
actively cooperate with your expansion. Which

00:42:46.760 --> 00:42:49.420
is exactly why Mark Cuban has been very publicly

00:42:49.420 --> 00:42:52.039
pushing the government to change its fee structures.

00:42:52.139 --> 00:42:55.260
Specifically advocating for the waiver of the

00:42:55.260 --> 00:42:58.179
FDA generic drug approval fee. The general public

00:42:58.179 --> 00:43:01.059
probably doesn't realize this, but it costs a

00:43:01.059 --> 00:43:03.280
fortune just to ask the government for permission

00:43:03.280 --> 00:43:06.219
to make a generic drug. Right now, a manufacturer

00:43:06.219 --> 00:43:10.340
has to pay roughly $360 ,000 in user fees just

00:43:10.340 --> 00:43:13.239
to get the FDA to review an application to produce

00:43:13.239 --> 00:43:15.440
a generic medication that has already been proven

00:43:15.440 --> 00:43:18.440
safe for decades. Cuban argues that waiving this

00:43:18.440 --> 00:43:21.099
exorbitant fee for domestic producers would drastically

00:43:21.099 --> 00:43:23.519
lower the barrier to entry, allowing companies

00:43:23.519 --> 00:43:26.000
to rapidly expand production into low -margin

00:43:26.000 --> 00:43:28.360
rare disease drugs and other critical shortage

00:43:28.360 --> 00:43:31.199
areas without taking a massive financial hit

00:43:31.199 --> 00:43:34.079
just on the paperwork. And this push for domestic

00:43:34.079 --> 00:43:36.800
manufacturing isn't just a pet project of Mark

00:43:36.800 --> 00:43:39.420
Cuban. It isn't happening in a vacuum. If we

00:43:39.420 --> 00:43:42.800
zoom out and look at the macro trends, the MCPDC

00:43:42.800 --> 00:43:45.579
Dallas plant is just the vanguard of a much larger

00:43:45.579 --> 00:43:49.059
historic boom in domestic pharmaceutical manufacturing

00:43:49.059 --> 00:43:53.500
spanning 2025 and 2026. The entire global industry

00:43:53.500 --> 00:43:56.679
is experiencing a paradigm shift. They are collectively

00:43:56.679 --> 00:43:59.440
recognizing that the era of hyper globalized

00:43:59.440 --> 00:44:02.860
brittle supply chains prioritizing absolute lowest

00:44:02.860 --> 00:44:06.000
cost over reliability is over. The capital commitments

00:44:06.000 --> 00:44:08.880
being made by the major players right now. are

00:44:08.880 --> 00:44:10.980
staggering. The numbers coming from the industry

00:44:10.980 --> 00:44:13.679
trackers are genuinely historic. We are talking

00:44:13.679 --> 00:44:16.260
about hundreds of billions of dollars being poured

00:44:16.260 --> 00:44:18.599
into American soil to build factories. Merck

00:44:18.599 --> 00:44:21.219
is committing over 70 billion dollars for domestic

00:44:21.219 --> 00:44:23.519
investments, which includes building a massive

00:44:23.519 --> 00:44:26.079
new manufacturing center of excellence. Eli Lilly

00:44:26.079 --> 00:44:29.360
is pledging 27 billion dollars to construct four

00:44:29.360 --> 00:44:31.940
advanced mega sites. AstraZeneca just unveiled

00:44:31.940 --> 00:44:34.659
a 50 billion dollar investment plan. Johnson

00:44:34.659 --> 00:44:37.960
& Johnson is committing 55 billion. Why is the

00:44:37.960 --> 00:44:40.559
entire industry suddenly rushing to build massive

00:44:40.559 --> 00:44:43.320
expensive factories in the U .S. all at the same

00:44:43.320 --> 00:44:46.500
time? There is a confluence of powerful drivers

00:44:46.500 --> 00:44:49.579
behind this macro shift. First and foremost is

00:44:49.579 --> 00:44:52.079
the lingering supply chain trauma of the pandemic.

00:44:52.409 --> 00:44:55.170
Companies realized that relying on a single factory

00:44:55.170 --> 00:44:58.230
in a geopolitical rivals territory is an existential

00:44:58.230 --> 00:45:00.250
threat to their business. They are forced to

00:45:00.250 --> 00:45:03.110
prioritize physical resilience. Second, there

00:45:03.110 --> 00:45:05.909
is a massive surging shift in consumer demand.

00:45:06.130 --> 00:45:08.949
We are seeing the explosion of novel complex

00:45:08.949 --> 00:45:12.190
therapies, specifically the new class of GLP

00:45:12.190 --> 00:45:15.730
-1 obesity. and diabetes drugs. Along with incredibly

00:45:15.730 --> 00:45:18.210
advanced treatments like Sogar T -cell therapies

00:45:18.210 --> 00:45:20.590
and gene therapies. These are not simple pills.

00:45:20.769 --> 00:45:23.789
They require high capacity, highly sterile bioprocessing

00:45:23.789 --> 00:45:25.730
environments that are vastly better suited for

00:45:25.730 --> 00:45:28.130
strict domestic oversight and a highly educated

00:45:28.130 --> 00:45:31.610
local workforce. Third, macroeconomic and geopolitical

00:45:31.610 --> 00:45:34.030
tensions are forcing the issue. The threat of

00:45:34.030 --> 00:45:36.369
sweeping trade policies and tariffs is very real.

00:45:36.670 --> 00:45:38.969
Current analysis suggests that proposed U .S.

00:45:39.150 --> 00:45:42.409
tariffs could potentially add up to $19 billion.

00:45:42.599 --> 00:45:45.940
in excess costs to the global pharma supply chain.

00:45:46.360 --> 00:45:48.699
It makes immense financial sense for these multinational

00:45:48.699 --> 00:45:51.800
companies to build locally to avoid those massive

00:45:51.800 --> 00:45:54.840
penalties and ensure uninterrupted access to

00:45:54.840 --> 00:45:57.099
the lucrative American market. And the federal

00:45:57.099 --> 00:45:59.539
government isn't just sitting back. They are

00:45:59.539 --> 00:46:02.280
actively greasing the wheels to accelerate this

00:46:02.280 --> 00:46:05.000
onshore. They know that building a bioprocessing

00:46:05.000 --> 00:46:07.079
plant is a regulatory nightmare that usually

00:46:07.079 --> 00:46:11.099
takes years. In May of 2025, a sweeping executive

00:46:11.099 --> 00:46:13.800
order was passed specifically directing the FDA

00:46:13.800 --> 00:46:16.760
to slash red tape and streamline the approval

00:46:16.760 --> 00:46:19.099
processes for U .S. based drug manufacturing

00:46:19.099 --> 00:46:21.559
plants. And they followed that up in August of

00:46:21.559 --> 00:46:24.760
2025 by launching the FDA PreCheck initiative.

00:46:24.960 --> 00:46:26.980
This program provides pharmaceutical companies

00:46:26.980 --> 00:46:29.239
with early frequent direct communication and

00:46:29.239 --> 00:46:31.980
feedback from regulators during the actual construction

00:46:31.980 --> 00:46:34.829
and process design phases of the facility. Drastically

00:46:34.829 --> 00:46:37.110
accelerating the timeline from breaking ground

00:46:37.110 --> 00:46:40.230
to fully operational production. However, this

00:46:40.230 --> 00:46:43.829
massive industrial shift raises a critical, potentially

00:46:43.829 --> 00:46:46.409
troubling question for you the listener to consider

00:46:46.409 --> 00:46:49.489
regarding the future of your pharmacy bill. Onshore

00:46:49.489 --> 00:46:52.150
-ing undeniably fixes the physical shortage risk.

00:46:52.690 --> 00:46:55.590
It undeniably fixes the severe quality control

00:46:55.590 --> 00:46:57.889
issues that stem from poorly regulated offshore

00:46:57.889 --> 00:47:00.429
factories. But operating a high -tech facility

00:47:00.429 --> 00:47:03.530
with American labor, paying American wages, and

00:47:03.530 --> 00:47:06.809
adhering to strict domestic EPA and OSHA standards

00:47:06.809 --> 00:47:09.730
is fundamentally and permanently more expensive

00:47:09.730 --> 00:47:12.949
than running a sweatshop factory overseas. Analysts

00:47:12.949 --> 00:47:14.949
are warning that these heightened permanent domestic

00:47:14.949 --> 00:47:17.110
manufacturing costs, combined with the hundreds

00:47:17.110 --> 00:47:18.909
of billions of dollars currently being spent

00:47:18.909 --> 00:47:20.989
on capital expenditures to build the plants,

00:47:21.349 --> 00:47:23.550
could ultimately raise the baseline floor price

00:47:23.550 --> 00:47:26.150
of generic drugs across the board. So the crucial

00:47:26.150 --> 00:47:29.050
question becomes, will the massive savings generated

00:47:29.050 --> 00:47:32.250
by eliminating the greedy PBM middlemen be enough

00:47:32.250 --> 00:47:34.869
to offset the structurally higher cost of domestic

00:47:34.869 --> 00:47:37.309
manufacturing? Can we actually have a system

00:47:37.309 --> 00:47:39.550
that provides resilient, high -quality American

00:47:39.550 --> 00:47:41.530
-made drugs that are still affordable for the

00:47:41.530 --> 00:47:44.530
average citizen? That is the multi -billion dollar

00:47:44.530 --> 00:47:46.590
question that will define the next decade of

00:47:46.590 --> 00:47:48.809
health care. And while the physical supply chain

00:47:48.809 --> 00:47:51.170
is rebuilding itself from the ground up, the

00:47:51.170 --> 00:47:53.769
intricate insurance landscape is simultaneously

00:47:53.769 --> 00:47:56.809
fracturing under the weight of new complex legislation.

00:47:57.030 --> 00:47:59.070
We really need to pivot and look at what is happening

00:47:59.070 --> 00:48:01.829
with the government's role in this specifically

00:48:01.829 --> 00:48:05.389
Medicare Part D. Because the unintended consequences

00:48:05.389 --> 00:48:08.190
of recent policy are hitting seniors incredibly

00:48:08.190 --> 00:48:11.539
hard right now. According to deep granular analysis

00:48:11.539 --> 00:48:13.820
from our industry sources, the Medicare Part

00:48:13.820 --> 00:48:17.179
D standalone prescription drug plan market is

00:48:17.179 --> 00:48:19.780
essentially undergoing a collapse. And this collapse

00:48:19.780 --> 00:48:22.719
is a direct, albeit unintended, result of the

00:48:22.719 --> 00:48:25.659
Inflation Reduction Act or the IRA. The IRA was

00:48:25.659 --> 00:48:27.800
celebrated for capping out -of -pocket costs

00:48:27.800 --> 00:48:30.840
for seniors. But to achieve that, it fundamentally

00:48:30.840 --> 00:48:33.260
redesigned the liability structure for the insurance

00:48:33.260 --> 00:48:36.179
plans themselves. Prior to the IRA, if a senior

00:48:36.179 --> 00:48:38.639
had catastrophic drug costs, the federal government

00:48:38.760 --> 00:48:41.539
Medicare absorbed roughly 80 % of that liability

00:48:41.539 --> 00:48:44.480
in the catastrophic phase. The IRA flipped that

00:48:44.480 --> 00:48:47.460
entirely. It capped the seniors out of pocket

00:48:47.460 --> 00:48:50.440
spend, but shifted massive financial liability

00:48:50.440 --> 00:48:53.619
directly onto the private insurance plans. Forcing

00:48:53.619 --> 00:48:56.559
them to absorb roughly 60 % of those catastrophic

00:48:56.559 --> 00:48:58.739
costs. So the government told the private insurance

00:48:58.739 --> 00:49:00.679
companies, we aren't covering the worst case

00:49:00.679 --> 00:49:03.539
scenarios anymore, you are. How did the massive

00:49:03.539 --> 00:49:06.000
insurance companies react to suddenly being on

00:49:06.000 --> 00:49:08.360
the hook for billions of dollars in new liability?

00:49:08.539 --> 00:49:11.460
They bailed. They aggressively exited the market

00:49:11.460 --> 00:49:14.139
or consolidated their offerings to shed risk.

00:49:14.440 --> 00:49:18.539
In 2026, there will be only 360 standalone prescription

00:49:18.539 --> 00:49:21.420
drug plans available nationwide. That represents

00:49:21.420 --> 00:49:25.260
a massive 22 % drop in available plans from just

00:49:25.260 --> 00:49:27.960
2025. And the resulting market consolidation

00:49:27.960 --> 00:49:30.579
is terrifying from a competitive standpoint.

00:49:30.760 --> 00:49:33.760
Just four massive companies, Centene, HCSC, Humana,

00:49:33.940 --> 00:49:36.280
and United Health, will control a staggering

00:49:36.280 --> 00:49:39.280
84 % of the entire prescription drug plan market.

00:49:39.550 --> 00:49:42.230
With drastically less competition and substantially

00:49:42.230 --> 00:49:44.349
higher liabilities, these remaining plans are

00:49:44.349 --> 00:49:46.449
aggressively shifting costs wherever they legally

00:49:46.449 --> 00:49:49.070
can. Seniors are facing higher deductibles right

00:49:49.070 --> 00:49:51.530
out of the gate, and a much greater reliance

00:49:51.530 --> 00:49:54.929
on steep coinsurance percentages for non -specialty

00:49:54.929 --> 00:49:58.090
brand drugs. The bitter irony is that if a Medicare

00:49:58.090 --> 00:50:01.010
beneficiary doesn't have catastrophic costs,

00:50:01.469 --> 00:50:04.190
if they don't hit the new $2 ,000 annual out

00:50:04.190 --> 00:50:06.980
-of -pocket cap, They may actually end up paying

00:50:06.980 --> 00:50:09.579
significantly more for their daily routine medications

00:50:09.579 --> 00:50:11.719
this year than they did before the reform was

00:50:11.719 --> 00:50:14.260
passed. It is incredibly frustrating to watch.

00:50:14.780 --> 00:50:17.099
You pass sweeping legislation with the intent

00:50:17.099 --> 00:50:19.820
to help vulnerable people and the market just

00:50:19.920 --> 00:50:23.119
contorts itself, consolidates power, and squeezes

00:50:23.119 --> 00:50:24.960
them somewhere else to maintain profit margins.

00:50:25.320 --> 00:50:27.480
We are also seeing a similar distortion with

00:50:27.480 --> 00:50:31.500
the 340B drug pricing program. This was originally

00:50:31.500 --> 00:50:33.500
a very targeted program designed specifically

00:50:33.500 --> 00:50:36.380
to help true safety net hospitals buy drugs at

00:50:36.380 --> 00:50:38.539
a steep discount so they could afford to serve

00:50:38.539 --> 00:50:41.360
uninsured and vulnerable populations. But recent

00:50:41.360 --> 00:50:43.400
reports show the program is expanding wildly

00:50:43.400 --> 00:50:46.079
beyond its original intent. It is being driven

00:50:46.079 --> 00:50:49.559
by the strategic choices of massive wealthy hospital

00:50:49.559 --> 00:50:53.059
systems aggressively buying up independent wealthy

00:50:53.059 --> 00:50:56.250
suburban clinics. just so they can claim the

00:50:56.250 --> 00:50:58.829
three, four to be discount across a wider patient

00:50:58.829 --> 00:51:02.269
base. This rampant vertical integration is fueling

00:51:02.269 --> 00:51:04.750
higher federal spending and actively raising

00:51:04.750 --> 00:51:07.269
costs for commercial payers in the private market.

00:51:07.449 --> 00:51:09.969
In this incredibly chaotic, rapidly shifting

00:51:09.969 --> 00:51:12.329
environment of collapsing insurance markets and

00:51:12.329 --> 00:51:15.050
expanding loopholes, alternative tech solutions

00:51:15.050 --> 00:51:17.909
and policy partnerships are becoming vital survival

00:51:17.909 --> 00:51:20.570
strategies. That is exactly right. Innovative

00:51:20.570 --> 00:51:23.489
disruptors like MCC PDC aren't just relying on

00:51:23.489 --> 00:51:25.570
their brick and mortar pharmacy alliances and

00:51:25.570 --> 00:51:28.170
a single manufacturing plant in Dallas. They

00:51:28.170 --> 00:51:30.309
are heavily leveraging advanced technology to

00:51:30.309 --> 00:51:32.699
scale their operations efficiently. They recently

00:51:32.699 --> 00:51:34.739
formed a major partnership with a company called

00:51:34.739 --> 00:51:38.340
MedChat .ai to deploy sophisticated artificial

00:51:38.340 --> 00:51:41.099
intelligence customer care agents. When you are

00:51:41.099 --> 00:51:42.860
running a direct -to -consumer healthcare model

00:51:42.860 --> 00:51:45.340
that serves millions of patients, patient support

00:51:45.340 --> 00:51:47.360
is critical. People have questions about their

00:51:47.360 --> 00:51:50.059
prescriptions. AI allows them to scale that support

00:51:50.059 --> 00:51:53.139
infinitely and instantaneously without exponentially

00:51:53.139 --> 00:51:55.239
increasing their human overhead costs. Which

00:51:55.239 --> 00:51:57.719
is absolutely vital for maintaining that incredibly

00:51:57.719 --> 00:52:00.730
slim, transparent 15 % profit margin. They have

00:52:00.730 --> 00:52:03.469
also formed strategic alliances with other domestic

00:52:03.469 --> 00:52:06.710
manufacturers like Alkom Laboratories to specifically

00:52:06.710 --> 00:52:09.670
focus on using automated AI driven platforms

00:52:09.670 --> 00:52:13.030
to onshore the production of highly essential,

00:52:13.110 --> 00:52:15.969
vulnerable medicines targeting specific shortage

00:52:15.969 --> 00:52:19.250
drugs like lidocaine and diltiesm. And we absolutely

00:52:19.250 --> 00:52:22.230
cannot discuss the landscape of 2026 without

00:52:22.230 --> 00:52:24.570
addressing the massive shifts in the political

00:52:24.570 --> 00:52:27.199
landscape. Now, just to be absolutely clear to

00:52:27.199 --> 00:52:30.039
you, our listener, we do not endorse any political

00:52:30.039 --> 00:52:32.099
viewpoints, candidates or administrations on

00:52:32.099 --> 00:52:34.559
this deep dive. Right. Our mandate is strictly

00:52:34.559 --> 00:52:37.440
to analyze the factual policy framework and the

00:52:37.440 --> 00:52:39.659
economic market reactions precisely as they are

00:52:39.659 --> 00:52:42.159
presented in the data. With that strict impartiality

00:52:42.159 --> 00:52:44.800
in mind, a major development rocking the industry

00:52:44.800 --> 00:52:46.820
is the announcement of the Trump -Rx partnership.

00:52:47.539 --> 00:52:50.360
What exactly is the mechanism of this new program?

00:52:50.559 --> 00:52:53.079
The TrumperX platform, which is slated to launch

00:52:53.079 --> 00:52:56.420
in early 2026, is fundamentally designed as a

00:52:56.420 --> 00:52:59.019
government -sponsored direct purchasing search

00:52:59.019 --> 00:53:01.960
engine. It is crucial to understand that it is

00:53:01.960 --> 00:53:04.239
not a direct seller. or a physical distributor

00:53:04.239 --> 00:53:06.699
of drugs itself. Instead, it acts as a massive

00:53:06.699 --> 00:53:09.860
referral hub that directs patients toward transparent

00:53:09.860 --> 00:53:12.539
direct -to -consumer websites like Cost Plus

00:53:12.539 --> 00:53:15.559
Drugs. The underlying strategy is to use the

00:53:15.559 --> 00:53:18.159
immense reach of a government platform to drive

00:53:18.159 --> 00:53:21.059
massive consumer volume toward these transparent

00:53:21.059 --> 00:53:24.280
low -cost options, theoretically starving the

00:53:24.280 --> 00:53:27.059
opaque PBMs of their transaction volume. Pfizer

00:53:27.059 --> 00:53:30.360
was notably one of the first major legacy pharmaceutical

00:53:30.360 --> 00:53:33.280
manufacturers to publicly sign onto this initiative.

00:53:33.699 --> 00:53:36.199
And the geopolitical angle here is deeply intertwined.

00:53:36.360 --> 00:53:39.380
By joining the Trump -Rex hub, Pfizer successfully

00:53:39.380 --> 00:53:42.159
secured a three -year grace period during which

00:53:42.159 --> 00:53:44.320
its imported products will not be subject to

00:53:44.320 --> 00:53:46.500
the sweeping new tariffs. Allowing them to avoid

00:53:46.500 --> 00:53:48.980
billions in those supply chain penalties we discussed

00:53:48.980 --> 00:53:51.460
earlier. It is fascinating to see how policy

00:53:51.460 --> 00:53:53.559
tariffs and correct your consumer models are

00:53:53.559 --> 00:53:56.719
all colliding. Mark Cuban's public reaction to

00:53:56.719 --> 00:53:58.579
the Trump -Rex announcement was really interesting

00:53:58.579 --> 00:54:01.119
to dissect. He essentially gave the program a

00:54:01.119 --> 00:54:03.679
B grade on social media. His reasoning for the

00:54:03.679 --> 00:54:06.280
slightly muted grade was based on market indicators.

00:54:07.320 --> 00:54:10.420
He noted that the stock prices of the major publicly

00:54:10.420 --> 00:54:14.199
traded PBMs didn't immediately plummet when the

00:54:14.199 --> 00:54:16.460
platform was announced. To him, that implies

00:54:16.460 --> 00:54:18.500
the broader financial market doesn't believe

00:54:18.500 --> 00:54:20.920
the big middlemen are facing an immediate existential

00:54:20.920 --> 00:54:23.760
threat from a search engine. However, Cuban also

00:54:23.760 --> 00:54:26.940
pragmatically noted that being listed on a massive

00:54:26.940 --> 00:54:30.139
government referral hub will undeniably drive

00:54:30.139 --> 00:54:33.579
massive new patient volume directly to cost plus

00:54:33.579 --> 00:54:37.159
drugs. And in his strict cost plus economic model,

00:54:37.480 --> 00:54:39.840
higher volume directly equates to greater purchasing

00:54:39.840 --> 00:54:42.539
power, which ultimately results in even lower

00:54:42.539 --> 00:54:44.820
acquisition costs for patients. But prominent

00:54:44.820 --> 00:54:47.400
industry analysts remain highly cautious about

00:54:47.400 --> 00:54:49.780
the ultimate systemic impact. In the research,

00:54:50.059 --> 00:54:52.380
Jesse Mendelson, a senior executive at the revenue

00:54:52.380 --> 00:54:54.480
management firm Model N, pointed it out that

00:54:54.480 --> 00:54:57.000
the true long -term impact of trunk Rx remains

00:54:57.000 --> 00:54:59.860
to be seen. His core argument. is that the vast

00:54:59.860 --> 00:55:02.780
overwhelming majority of Americans still fundamentally

00:55:02.780 --> 00:55:04.900
rely on their commercial insurance to pay for

00:55:04.900 --> 00:55:07.719
their drugs. A direct -to -consumer search engine

00:55:07.719 --> 00:55:11.139
is a fantastic tool that vastly expands access

00:55:11.139 --> 00:55:13.780
for the uninsured or for patients who are willing

00:55:13.780 --> 00:55:16.079
to pay cash outside of their high deductibles.

00:55:16.219 --> 00:55:18.900
But it doesn't fundamentally rewrite the deeply

00:55:18.900 --> 00:55:21.780
entrenched complex dynamics of how commercial

00:55:21.780 --> 00:55:24.929
insurers re -boost for drugs, or how massive

00:55:24.929 --> 00:55:27.630
pharmaceutical manufacturers incentivize those

00:55:27.630 --> 00:55:30.690
payers through the opaque rebate system. It creates

00:55:30.690 --> 00:55:33.449
a viable alternative pathway for many, but it

00:55:33.449 --> 00:55:36.329
is not necessarily a complete systemic replacement

00:55:36.329 --> 00:55:39.489
for the existing multi -trillion dollar insurance

00:55:39.489 --> 00:55:41.309
machine. Okay, let's bring this all together.

00:55:41.500 --> 00:55:43.980
We have covered a truly massive amount of ground

00:55:43.980 --> 00:55:46.519
today. We are witnessing a monumental historic

00:55:46.519 --> 00:55:48.960
paradigm shift in exactly how we get our medicine

00:55:48.960 --> 00:55:51.219
in this country. The pharmaceutical supply chain

00:55:51.219 --> 00:55:54.039
is slowly agonizingly, but definitely moving

00:55:54.039 --> 00:55:57.039
away from a dark, broken system defined by opaque

00:55:57.039 --> 00:55:59.820
rebates, hyper fragile offshore supply lines

00:55:59.820 --> 00:56:02.619
and total PVM dominance. We are visibly moving

00:56:02.619 --> 00:56:05.179
toward a future defined by advanced domestic

00:56:05.179 --> 00:56:08.159
robotic manufacturing, AI integration and radically

00:56:08.159 --> 00:56:11.739
transparent cost plus economics. seeing independent

00:56:11.739 --> 00:56:14.739
community pharmacies thrown a vital lifeline,

00:56:15.460 --> 00:56:17.900
and everyday patients saving thousands of dollars

00:56:17.900 --> 00:56:21.300
on life -saving generic drugs. This shift from

00:56:21.300 --> 00:56:24.739
opaqueness to transparency is real, and it is

00:56:24.739 --> 00:56:27.170
accelerating. This raises an important question

00:56:27.170 --> 00:56:29.809
for you to ask yourself regarding your own health

00:56:29.809 --> 00:56:32.670
care footprint. Take a hard look at your employer's

00:56:32.670 --> 00:56:35.349
insurance plan. Look closely at your deductibles,

00:56:35.510 --> 00:56:37.849
your copays, and the specific rules regarding

00:56:37.849 --> 00:56:40.250
where you are allowed to fill your prescriptions.

00:56:40.449 --> 00:56:43.050
Ask yourself, and maybe even ask your HR department,

00:56:43.250 --> 00:56:45.929
are you unknowingly paying inflated out -of -pocket

00:56:45.929 --> 00:56:48.530
costs at the pharmacy counter just to subsidize

00:56:48.530 --> 00:56:50.869
corporate rebate checks? Are you the one secretly

00:56:50.869 --> 00:56:53.269
funding the regressive tax of modern health care?

00:56:53.440 --> 00:56:56.199
The tools for absolute price transparency now

00:56:56.199 --> 00:56:59.159
exist in the open market. The onus is increasingly

00:56:59.159 --> 00:57:02.019
shifting onto employers, plan sponsors, and individual

00:57:02.019 --> 00:57:04.320
patients to aggressively demand that transparency

00:57:04.320 --> 00:57:06.800
from their benefit providers. Absolutely. The

00:57:06.800 --> 00:57:08.840
curtain has finally been pulled back, and we

00:57:08.840 --> 00:57:11.260
simply cannot unsee how the machine actually

00:57:11.260 --> 00:57:13.539
works. But I want to leave you with one final

00:57:13.539 --> 00:57:15.699
provocative thought to mull over. Something that

00:57:15.699 --> 00:57:17.900
builds on everything we've dissected today, but

00:57:17.900 --> 00:57:20.320
pushes the implications a step further into the

00:57:20.320 --> 00:57:23.670
future. If transparent cost plus price becomes

00:57:23.670 --> 00:57:27.309
the universal mandatory standard. If Mark Cuban's

00:57:27.309 --> 00:57:30.789
vision completely wins out and the massive inflated

00:57:30.789 --> 00:57:33.789
profit margins generated by PBMs and complex

00:57:33.789 --> 00:57:36.110
patent thickets are entirely wiped out of the

00:57:36.110 --> 00:57:38.630
system. What happens to the billions and billions

00:57:38.630 --> 00:57:40.849
of dollars required to fund the next generation

00:57:40.849 --> 00:57:43.769
of breakthrough miracle drugs? Developing a novel

00:57:43.769 --> 00:57:46.989
gene therapy or a cure for Alzheimer's requires

00:57:46.989 --> 00:57:50.050
immense high -risk capital. Will true ruthless

00:57:50.050 --> 00:57:53.070
price transparency accidentally kill the massive

00:57:53.070 --> 00:57:55.630
financial incentives required for future clinical

00:57:55.630 --> 00:57:57.769
innovation? It is a heavy question to think about

00:57:57.769 --> 00:57:59.650
the next time you pick up a prescription. Thank

00:57:59.650 --> 00:58:01.449
you so much for joining us on this Deep Dive.

00:58:01.530 --> 00:58:02.409
We will catch you next time.